# Baughman v. Secretary of Health and Human Services

> United States Court of Federal Claims · June 1, 2026

URL: https://www.frixlaw.com/law-library/cases/11335904

## Case

- **Court:** United States Court of Federal Claims
- **Decided:** June 1, 2026
- **Precedential status:** Unpublished
- **Opinion:** Opinion
- **Judges:** Daniel T. Horner
- **Cited by:** 0 later opinions in the Frix Law Library

## Citator (automated)

- No negative treatment found by the automated citator. That is not the same as a confirmation that the case is good law; read the citing cases.
- Full citator and citing cases: https://www.frixlaw.com/law-library/cases/11335904

## How later opinions describe it (automated extraction)

- holding the special master did 32 not err in resolving the case pursuant to Althen prong two when respondent conceded that petitioner met Althen prong three
- noting the special master’s comment that “IOM reports are favored, although not dispositive, in the Vaccine Program,” then affirming special master’s decision
- reasoning that “nothing . . . mandates that the testimony of a treating physician is sacrosanct—that it must be accepted in its entirety and cannot be rebutted”

## Opinion text

In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 18-591V
Filed: March 17, 2026

Special Master Horner
BRENDA BAUGHMAN,

Petitioner,
v.

SECRETARY OF HEALTH AND
HUMAN SERVICES,

Respondent.

Mark Theodore Sadaka, Law Offices of Sadaka Associates, LLC, Englewood, NJ, for
petitioner.
Lauren Kells, U.S. Department of Justice, Washington, DC, for respondent.

DECISION1

On April 25, 2018, petitioner, Brenda Baughman, filed a petition under the
National Childhood Vaccine Injury Act, 42 U.S.C. § 300aa-10, et seq. (2012).2 (ECF
No. 1.) Petitioner alleges that she suffered vaccine-induced polyneuropathy after
receiving the pneumococcal (“Prevnar 13”) and tetanus, diphtheria, and acellular
pertussis (“Tdap”) vaccines on May 10, 2016. (Id.) For the reasons set forth below, I
conclude that petitioner is not entitled to an award of compensation.

I. Applicable Statutory Scheme

Under the National Vaccine Injury Compensation Program, compensation
awards are made to individuals who have suffered injuries after receiving vaccines. In
general, to gain an award, a petitioner must make a number of factual demonstrations,
1 Because this document contains a reasoned explanation for the action taken in this case, it must be

made publicly accessible and will be posted on the United States Court of Federal Claims' website, and/or
at https://www.govinfo.gov/app/collection/uscourts/national/cofc, in accordance with the E-Government
Act of 2002. 44 U.S.C. § 3501 note (2018) (Federal Management and Promotion of Electronic
Government Services). This means the document will be available to anyone with access to the
internet. In accordance with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact
medical or other information, the disclosure of which would constitute an unwarranted invasion of privacy.
If, upon review, I agree that the identified material fits within this definition, I will redact such material from
public access.
2 Within this decision, all citation to § 300aa will be the relevant sections of the Vaccine Act at 42 U.S.C.

§ 300aa-10-34.

1
including showing that an individual received a vaccination covered by the statute;
received it in the United States; suffered a serious or long-standing injury; and has
received no previous award or settlement on account of the injury. Finally – and the key
question in most cases under the Program – the petitioner must also establish a causal
link between the vaccination and the injury. In some cases, the petitioner may simply
demonstrate the occurrence of what has been called a “Table Injury.” That is, it may be
shown that the vaccine recipient suffered an injury of the type enumerated in the
“Vaccine Injury Table,” corresponding to the vaccination in question, within an
applicable time period following the vaccination also specified in the Table. If so, the
Table Injury is presumed to have been caused by the vaccination, and the petitioner is
automatically entitled to compensation, unless it is affirmatively shown that the injury
was caused by some factor other than the vaccination. § 300aa-13(a)(1); § 300aa-
11(c)(1)(C)(i); § 300aa-14(a).

In many cases, however, the vaccine recipient may have suffered an injury not of
the type covered in the Vaccine Injury Table. In such instances, an alternative means
exists to demonstrate entitlement to a Program award. That is, the petitioner may gain
an award by showing that the recipient’s injury was “caused-in-fact” by the vaccination
in question. § 300aa-13(a)(1)(B); § 300aa-11(c)(1)(C)(ii). In such a situation, of course,
the presumptions available under the Vaccine Injury Table are inoperative. The burden
is on the petitioner to introduce evidence demonstrating that the vaccination actually
caused the injury in question. Althen v. Sec’y of Health & Human Servs., 418 F.3d
1274, 1278 (Fed. Cir. 2005); Hines ex rel. Sevier v. Sec’y of Health & Human Servs.,
940 F.2d 1518, 1525 (Fed. Cir. 1991). In this case, petitioner has not alleged an injury
that appears on the Vaccine Injury Table. 42 C.F.R. § 100.3(a). Therefore, petitioner
must demonstrate causation-in-fact.

The showing of causation-in-fact must satisfy the “preponderance of the
evidence” standard, the same standard ordinarily used in tort litigation.
§ 300aa-13(a)(1)(A); see also Althen, 418 F.3d at 1278-79; Hines, 940 F.2d at 1525.
Under that standard, petitioner must show that it is “more probable than not” that the
vaccination was the cause of the injury. Althen, 418 F.3d at 1279. She need not show
that the vaccination was the sole cause but must demonstrate that the vaccination was
at least a “substantial factor” in causing the condition at issue and was a “but for” cause.
Shyface v. Sec’y of Health & Human Servs., 165 F.3d 1344, 1352 (Fed. Cir. 1999).
Thus, petitioner must supply “proof of a logical sequence of cause and effect showing
that the vaccination was the reason for the injury.” Althen, 418 F.3d at 1278 (quoting
Grant v. Sec’y of Health & Human Servs., 956 F.2d 1144, 1148 (Fed. Cir. 1992)).
Ultimately, petitioner must satisfy what has come to be known as the Althen test, which
requires: (1) a medical theory causally connecting the vaccination and the injury; (2) a
logical sequence of cause and effect showing that the vaccination was the reason for
the injury; and (3) a showing of proximate temporal relationship between vaccination
and injury. Id.

A petitioner may not receive a Vaccine Program award based solely on his or her
assertions; rather, the petition must be supported by either medical records or by the

2
opinion of a competent physician. § 300aa-13(a)(1). Medical records are generally
viewed as particularly trustworthy evidence because they are created
contemporaneously with the treatment of the patient. Cucuras v. Sec’y of Health &
Human Servs., 993 F.2d 1525, 1528 (Fed. Cir. 1993). However, medical records and/or
statements of a treating physician’s views do not per se bind the special master to adopt
the conclusions of such an individual, even if they must be considered and carefully
evaluated. § 300aa-13(b)(1). A petitioner may rely upon circumstantial evidence. See
Althen, 418 F.3d at 1280. Moreover, the Althen court noted that a petitioner need not
necessarily supply evidence from medical literature supporting petitioner’s causation
contention, so long as the petitioner supplies the medical opinion of an expert. Id. at
1279-80. While scientific certainty is not required, that expert’s opinion must be based
on “sound and reliable” medical or scientific explanation. Boatmon v. Sec’y of Health &
Human Servs., 941 F.3d 1351, 1359 (Fed. Cir. 2019).

Cases in the Vaccine Program are assigned to special masters who are
responsible for “conducting all proceedings, including taking such evidence as may be
appropriate, making the requisite findings of fact and conclusions of law, preparing a
decision, and determining the amount of compensation, if any, to be awarded.” Vaccine
Rule 3(b)(1). Special masters must ensure each party has had a “full and fair
opportunity” to develop the record but are empowered to determine the format for taking
evidence based on the circumstances of each case, including having the discretion to
decide cases without an evidentiary hearing. Vaccine Rule 3(b)(2); Vaccine Rule 8(a);
Vaccine Rule 8(d). Special masters are not bound by common law or statutory rules of
evidence but must consider all relevant and reliable evidence in keeping with
fundamental fairness to both parties. Vaccine Rule 8(b)(1).

II. Procedural History

This case was initially assigned to another special master. (ECF No. 4.) After
filing her petition, petitioner filed medical records and an affidavit. (ECF No. 7, 20; Exs.
1-14.) In February of 2019, petitioner confirmed she had filed all her medical records.
(ECF No. 22.) Respondent filed his Rule 4(c) report, recommending against
compensation in June of 2019 and petitioner was directed to file an expert report. (ECF
No. 26.) Thereafter, on August 28, 2019, the case was reassigned to the undersigned.
(ECF Nos. 29-30.)

In June of 2020, petitioner filed additional medical records and an expert report
by neurologist Alberto Martinez-Arizala, M.D, along with supporting medical literature.
(ECF Nos. 37-38; Exs. 15-27.) Respondent filed two responsive expert reports with
supporting medical literature, one by neurologist Peter D. Donofrio, M.D. and another
from immunologist Penelope A. Morel, M.D. (ECF Nos. 42-44; Exs. A-D.) In January of
2021, petitioner filed additional medical records. (ECF No. 46; Ex. 28.) Petitioner also
filed a supplement expert report by Dr. Martinez-Arizala in April of 2021. (ECF Nos. 47-
48; Exs. 30-41.) Thereafter, respondent filed responsive expert reports from Dr.
Donofrio and Dr. Morel. (ECF No. 50; Exs. E-F.) On October 12, 2021, a Rule 5 status
conference was held, which addressed multiple areas of inquiry not fully addressed by

3
the expert reports filed at that time. (ECF No. 55.) The parties subsequently filed
supplemental reports responsive to that guidance between March and August of 2022.
(ECF Nos. 63-64, 67; Exs. 42-73, G-H.)

A two-day entitlement hearing was held in October of 2024. (See Transcript of
Proceedings (“Tr.”), at ECF Nos. 91-92.) Petitioner and the parties’ three experts
testified. Shortly before the hearing, petitioner filed three additional medical articles
(ECF No. 86; Exs. 74-76), which prompted an objection by respondent based on unfair
surprise (Tr. 5-7, 249-51). Based on the nature of the literature, I declined to preclude
the evidence but permitted respondent an opportunity to request additional proceedings
at a later date. (Id.) During the hearing, I observed that both parties had presented
literature that discussed the Institute of Medicine’s (IOM’s)3 1994 report addressing
adverse events associated with childhood vaccines. (Id. at 196-97.) Because I already
had familiarity with that publication, as well as a later 2012 IOM report on the same
subject matter, I filed the two publications as Court Exhibits I and II in the interest of
completeness and permitted the parties an opportunity to supplement the record in
response. (ECF No. 87; INSTITUTE OF MEDICINE, ADVERSE EVENTS ASSOCIATED WITH
CHILDHOOD VACCINES: EVIDENCE BEARING ON CAUSALITY (Kathleen R. Stratton et al. eds.,
1994) [hereinafter 1994 IOM report] (Ct. Ex. I); INSTITUTE OF MEDICINE, ADVERSE EFFECTS
OF VACCINES: EVIDENCE AND CAUSALITY (Kathleen Stratton et al. eds., 2012) [hereinafter
2012 IOM report] (Ct. Ex. II).) The parties subsequently confirmed they did not wish to
supplement the record. (ECF Nos. 88, 93.)

Post-hearing briefs were filed between January and March of 2025. (ECF Nos.
95, 97-98.) Accordingly, this case is now ripe for resolution.

III. Factual History

a. Medical Records

Before she received the vaccine at issue in this case, petitioner had a history of
osteoporosis and hyperlipidemia and saw her physician regularly for preventative care.

3 The Institute of Medicine (known as the National Academy of Medicine since 2015) is the medical arm of

the National Academy of Sciences. The National Academy of Sciences (“NAS”) was created by
Congress in 1863 to be an advisor to the federal government on scientific and technical matters (see An
Act to Incorporate the National Academy of Sciences, ch. 111, 12 Stat. 806 (1863)), and the Institute of
Medicine is an offshoot of the NAS established in 1970 to provide advice concerning medical issues.
When Congress enacted the Vaccine Act in 1986, it directed that the IOM conduct studies concerning
potential causal relationships between vaccines and illnesses. See § 300aa-1 note. Special masters
have observed that the IOM employs a standard for finding causation that is higher than what is required
by petitioner’s burden of proof. E.g., Raymo v. Sec’y of Health & Human Servs., No. 11-0654V, 2014 WL
1092274, at *21 n.39 (Fed. Cl. Spec. Mstr. Feb. 24, 2014). Accordingly, IOM reports and findings are
typically approached with caution and generally not treated as dispositive. Porter v. Sec’y of Health &
Human Servs., 663 F.3d 1242, 1252 (Fed. Cir. 2011) (noting the special master’s comment that “IOM
reports are favored, although not dispositive, in the Vaccine Program,” then affirming special master’s
decision). However, numerous prior cases have demonstrated that special masters may account for IOM
findings in reaching their decisions. See Harris v. Sec’y of Health & Human Servs., No. 18-944V, 2023
WL 2583393, at *3 n.6 (Fed. Cl. Spec. Mstr. Feb. 21, 2023) (collecting cases).

4
(Ex. 2, pp. 27-35, 40-41; Ex. 6, pp. 5-7.) Additionally, in April of 2014, petitioner saw a
chiropractor for left shoulder, elbow, and hand pain. (Ex. 8, pp. 1-14.) In May of 2015,
petitioner underwent an EKG after reporting “episodes of racing heart.” (Ex. 2, pp. 36-
38.) Petitioner returned to her chiropractor for her left shoulder, elbow, and arm in July
of 2015. (Ex. 8, pp. 15-16.) She continued her chiropractic care throughout the rest of
2015 and into 2016, during which she reported bilateral lower back pain, right hip
soreness, and right knee numbness, in addition to her original left shoulder and arm
pain. (Id. at 18-34.) By May 5, 2016, petitioner reported that her pain was improving.
(Id. at 33-34.) A urinalysis of May 2, 2016, showed trace amounts of blood, elevated
white blood cells and bacteria, and the presence of leukocyte esterase and nitrites. (Ex.
2, pp. 50-51.) She had a follow up appointment with her primary care physician on May
10, 2016, during which the results of her urinalysis were noted; however, petitioner was
asymptomatic, and her physician considered contamination as a potential explanation
for these results. (Id. at 22.)

Petitioner received the Tdap vaccine at issue in this case, along with a
pneumococcal vaccine, during her May 10, 2016 appointment. (Ex. 2, p. 25.) On May
23, 2016, petitioner reported worsening left sided thoracic and cervical pain, but her
right sided lumbar/sacral/pelvis pain was improving. (Ex. 8, pp. 35-36.) She described
her pain as “achy, dull, stiff,” and she associated her worsened symptoms with an
“airplane ride” during the prior week. (Id. at 36.) Her cervical pain radiated to her left
scapula and neck, and was associated with numbness in her bilateral scapula area, as
well as moderate paraspinal spasms on the left side. (Id.) Her thoracic and lumbar pain
was also associated with mild-to-moderate paraspinal spasms on the affected side.
(Id.) Her left thoracic and cervical rotation was limited. (Id.) Petitioner reported no
additional changes in her condition at her May 24, 2016 chiropractic appointment. (Id.
at 37-38.)

On May 26, 2016, petitioner reported to the emergency department with bilateral
leg pain that had been ongoing for five to seven days. (Ex. 6, p. 81.) Petitioner
described cramping, tingling, and numbness. (Id.) She explained that her pain began
after the flight from California about five days prior. (Id.) Petitioner underwent an
ultrasound, which showed no deep vein thrombosis, bilaterally. (Id. at 86.) She was
subsequently discharged in stable condition and with directions to follow up with her
primary care provider. (Id. at 86-87.) Petitioner returned to her chiropractor on May 28,
2016, where she reported that her left thoracic pain and right lumbar/sacral/pelvis pain
were increasing, though her cervical pain remained constant. (Ex. 8, p. 40.) She
reported no additional changes during her May 29, 2019 appointment. (Id. at 41-42.)

Petitioner reported to the emergency department again on May 30, 2016, with
bilateral leg pain for three days that waxed and waned. (Ex. 6, p. 88; Ex. 7, p. 7.) She
explained that “she has had lower back pain for the last couple [of] weeks that has now
radiated down her arms and legs bilaterally.” (Ex. 6, p. 88.) Petitioner explained that
she had recently traveled by plane and was concerned about blood clots; however, her
Doppler studies were negative. (Ex. 7, p. 7.) She noted numbness in her bilateral
hands and “twitching” in her legs. (Ex. 6, p. 88.) Her physical exam revealed right

5
“lumbar paraspinal tenderness,” and that she was unable to raise her legs. (Id. at 90.)
No motor sensory deficits were found; however, she did have paresthesias of the right
leg below her knee. (Id. at 91.) Differential diagnoses included cauda equina
syndrome, epidural abscess, vertebral fracture, degenerative disc disease, spondylosis,
spondylolisthesis, osteoporosis, arthritis, ALS, spinal neoplasm, spinal cord infections,
and muscle strains. (Id.) Petitioner was discharged in stable condition. (Id. at 92.)
However, petitioner returned to the emergency department later that same day,
explaining that she felt unsteady on her feet and that she had fallen. (Id. at 94.) She
reported a “rash on her torso, generalized weakness, and tingling in her hands and
legs.” (Id.) Petitioner underwent an MRI of the lumbar spine that revealed

1. Mild S-shaped scoliosis of the lumbar spine with mild to moderate
multilevel degenerative changes resulting in multilevel foraminal stenosis,
worse at L4-L5 where it is moderate, and minimal to mild canal stenosis,
worst at L4-L5. Of note, the left L5 nerve root is impinged between the disc
bulge and facet arthropathy. 2. No acute abnormalities in the lumbar spine.
3. Indeterminate lesion of L3, possibly atypical hemangioma, but if the
patient has a known primary malignancy metastatic disease cannot be
excluded. Consider postcontrast imaging on a nonemergent basis and
comparison with any prior studies would also be helpful.

(Ex. 7, p. 26.) Her diagnoses included acute dermatitis; osteoarthritis of lumbar spine,
unspecified spinal osteoarthritis complication status; and acute lumbar radiculopathy.
(Id. at 16.) The next day, petitioner was seen by her primary care physician for a follow
up on her leg and back pain and rash. (Ex. 2, p. 17.) She reported that her condition
began as tingling and numbness in her feet that impacted her balance. (Id.) She again
reported that her symptoms began after her trip. (Id.) Her primary care physician also
reported that she was taking Fosamax for her osteoporosis, hormone replacement
therapy for her menopausal symptoms, and fish oil and red yeast rice for her
hyperlipidemia. (Id. at 17-18.)

Petitioner had a chiropractic appointment on June 6, 2016, during which she
reported her left sided cervical pain remained with moderate left cervical paraspinal
spasms and moderate decreased left rotation and bending. (Ex. 8, p. 44.) Additionally,
she reported that her bilateral lumbar pain was getting worse, that she was having left
thoracic paraspinal spasms, and that her right bending lumbar motion was slightly
decreased. (Id.) Her thoracic pain was improving. (Id.) The next day, petitioner
returned to the chiropractor and reported the same symptoms. (Id. at 46.) Additionally,
she brought her MRI and reviewed it with her chiropractor. (Id.)

On June 9, 2016, petitioner had an orthopedic spine consultation with Dr. Gordon
Yee. (Ex. 4, pp. 43-44.) Dr. Yee recorded petitioner’s chief complaint as “[l]ow back
pain, bilateral lower extremity pain and tingling.” (Id. at 43.) Petitioner explained that
she has suffered from mild lower back pain for five years; however, three weeks ago,
her “back pain worsened and she had onset of bilateral lower extremity symptoms.”
(Id.) She reported that her increased pain was associated with “constant tingling in both

6
feet diffusely” and localized to her central lower lumbar spine and bilateral calves. (Id.)
Dr. Yee observed mild lumbar scoliosis, decreased lumbar range of motion, and “mild
tenderness over the lumbar spine posteriorly.” (Id.) Petitioner’s neurological
examination showed “positive Trendelenburg test with mild weakness of left hip
abductors,” but normal strength in all other lower extremity muscle groups. (Id.) Dr.
Yee reviewed petitioner’s MRI. (Id.) Petitioner was assessed with bilateral back and
lower extremity pain and tingling, lumbar degeneration, mild scoliosis, mild to moderate
L4-5 spinal stenosis, and an indeterminate bone marrow lesion at L3 vertebral body.
(Id. at 44.) Dr. Yee referred petitioner to physical therapy and prescribed hydrocodone.
(Id.) Petitioner had her initial physical therapy consultation on June 13, 2016. (Id. at
60.) At this initial consultation, petitioner reported that she was doing yard work and
cleaning in California and started experiencing discomfort on the flight home. (Id.) The
day after her flight, petitioner “woke up with significant pain with numbness/tingling in
her [bilateral] arms and legs.” (Id.) Petitioner’s physical exam noted that petitioner’s
posture was “[v]ariable; slouched, forward flexed posture throughout most of
examination,” and her range of motion tests revealed “[i]ncreased [bilateral lower
extremity] symptoms with forward flexion; increased lumbar symptoms with flexion.”
(Id.) On the right side, her hip flexion, knee flexion, knee extension, and ankle
dorsiflexion were recorded as 4+/5 and her ankle plantarflexion was recorded as 5/5.
(Id. at 61.) On the left, her hip flexion, knee flexion, knee extension, and ankle
dorsiflexion were 4+/5, and her ankle plantarflexion was 4-/5. (Id.) Her Lasegue’s
straight leg raise test was positive on both sides. (Id.)

Petitioner underwent another MRI on June 15, 2016, that revealed “[n]o
abnormal enhancement within the lumbar spine specifically no evidence of
enhancement corresponding to previous described indeterminate L3 lesion likely
representing atypical hemangioma,” and “[m]ild periarticular and endplate reactive
enhancement most prominent at L4-L5 endplate and L2-L3 facet articulations.” (Ex. 7,
p. 33.) Petitioner also underwent an x-ray of her lumbar spine on June 21, 2016, which
found “degenerative disk narrowing at L2-3, L3-4 and L4-5,” with the “most severe
narrowing at L4-5,” and “asymmetric disk narrowing at L4-5 on the left and mild L4-5
retrolisthesis.” (Ex. 4, p. 1.) Additionally, the x-ray identified mild lumbar scoliosis. (Id.)

Petitioner had a follow up appointment with Dr. Yee on June 21, 2016. (Ex. 4,
pp. 26-27.) Dr. Yee noted that petitioner’s pain had continued to worsen. (Id. at 26.)
Petitioner explained that her current symptoms were lower back pain, bilateral lower leg
pain, and constant tingling in her feet. (Id.) Her neurological exam revealed “weakness
in tibialis anterior bilaterally and [extensor hallucis longus] bilaterally all measuring
grade 4/5 strength,” along with “questionably decreased effort on motor testing.” (Id.)
Dr. Yee reviewed petitioner’s MRI and x-rays. (Id.) Petitioner was assessed with lower
back pain, “bilateral extremity pain and tingling,” bilateral possible mild weakness in her
tibialis anterior and extensor hallucis longus, lumbar degeneration and mild scoliosis,
“[m]ild to moderate L4-5 spinal stenosis,” and “[n]o enhancement with MRI contrast at
the L3 bone marrow lesion, most likely atypical hemangioma.” (Id. at 27.) Dr. Yee
ordered an electromyography and nerve conduction study (EMG/NCS) and prescribed
Hydrocodone. (Id.) Petitioner had a chiropractic appointment on June 22, 2016, where

7
she reported that her left thoracic pain was improving, there was no change to her left
cervical pain, and her bilateral lumbar/sacral/pelvis pain was getting worse. (Ex. 8, p.
48.) Petitioner presented to the emergency department on June 29, 2016, complaining
of pain “all over.” (Ex. 6, p. 96.) She reported that her symptoms began six weeks
prior, while on a road trip with her family. (Id.) She described “generalized pain and
muscle aches,” for which she was taking ibuprofen and oxycodone. (Id.) Her physical
exam revealed “1-2mm scattered erythematous lesions that are nonpalpable,” which
petitioner reported had been there for six weeks. (Id. at 98.)

On July 1, 2016, petitioner underwent an EMG/NCS of her lower extremities, with
Dr. Paulo Cancado. (Ex. 1, pp. 1-4.) The study showed evidence of an “[o]ngoing
partial denervation of the bilateral medial gastrocnemius and anterior tibialis muscles,
consistent with bilateral ongoing L4 and/or L5 and S1 radiculopathies,” or a moderate to
severe “axonal sensory and an axonal and demyelinating motor polyneuropathy.” (Id. at
1.) Dr. Cancado noted that he preferred the latter diagnosis. (Id. at 8.) Additionally, the
study showed “[p]rolongation of the bilateral H-reflux latencies, consistent with bilateral
S1 radiculopathies or a peripheral neuropathy.” (Id. at 1.) During her consultation, Dr.
Cancado recorded that petitioner had been experiencing pain, numbness, and
paresthesias in her distal lower extremities and hands for six to seven weeks. (Id. at 5.)
Her pain had been associated with a rash affecting the truck and neck area. (Id.)
Petitioner’s motor strength was recorded as “4/5 throughout, for exception of ankle dorsi
flexion which were 3+/5 bilaterally,” and her “[d]eep tendon reflexes were trac[able]
bilaterally symmetrically throughout and not obtainable [in the] ankles.” (Id. at 7.)
Additionally, Dr. Cancado noted that petitioner had bilateral hand numbness and
paresthesias and considered several differential diagnoses including “peripheral
neuropathy and entrapment neuropathies such as carpal tunnel syndrome and ulnar
neuropathy at the elbows.” (Id. at 7-8.)

Petitioner underwent a separate EMG/NCS for the numbness and paresthesias
in her upper extremities on July 2, 2016. (Ex. 1, pp. 9-12.) This study found a
moderate to severe bilateral “entrapment of the [m]edian nerves at the wrists, consistent
with [b]ilateral [c]arpal [t]unnel [s]yndromes,” and “[a]n axonal and demyelinating
sensorimotor polyneuropathy.” (Id. at 9.) Additionally, there was no evidence “of an
[u]lnar neuropathy at the elbows,” nor did the study “suggest a cervical radiculopathy (at
least motor) bilaterally.” (Id.) Dr. Cancado ordered blood tests for “potential causes of
peripheral neuropathy.” (Id. at 14.) On July 7, 2016, petitioner underwent a brain CT,
which showed “[n]o acute sinusitis,” and instead only “[m]inimal chronic inflammatory
change in the left sphenoid sinus.” (Ex. 14, p. 1.) The study was otherwise normal.
(Id.)

Petitioner had a follow up appointment with Dr. Cancado on July 11, 2016, for
“recent onset of peripheral neuropathy.” (Ex. 1, p. 69.) He noted that petitioner’s
EMG/NCS showed “axonal sensory and an axonal and demyelinating motor
polyneuropathy” in her lower extremities, and “polyneuropathy as well as bilateral carpal
tunnel syndromes” in her upper extremities. (Id.) He noted that petitioner had been
taking Oxycodone and Naproxen and was recently started on Amitriptyline. (Id.)

8
Petitioner reported that she “continu[ed] to have tingling and pain affecting both distal
lower extremities as well as tingling and stiffness in the hands.” (Id.) Dr. Cancado
described petitioner’s lab work as “unremarkable.” (Id.) Dr. Cancado’s impression
included polyneuropathy of unclear etiology, lumbosacral spondylosis, and bilateral
carpal tunnel syndromes. (Id. at 70.) On July 21, 2016, petitioner had a follow up
appointment with Dr. Yee for lower back pain, bilateral pain and tingling in her lower
extremities, “[p]ossible mild weakness in tibialis anterior bilaterally and EHL bilaterally
on previous examination,” and mild to moderate spinal stenosis at L4-5. (Ex. 4, p. 41.)
Petitioner reported that she had undergone blood tests and had been referred to a
specialist. (Id.) Petitioner’s exam revealed increased weakness in her lower
extremities, and “[m]otor strength in [her] tibialis anterior, EHL, and peronei all measure
grade 3/5 strength bilaterally.” (Id.) Dr. Yee reviewed petitioner’s EMG/NCS findings
and assessed petitioner with demyelinating polyneuropathy, tingling in her hands and
feet, weakness in her lower extremities, asymptomatic mild to moderate spinal stenosis
at L4-5, “mild lumbar scoliosis and multilevel lumbar degeneration,” and bilateral carpal
tunnel syndrome. (Id. at 41-42.) Petitioner’s antibody tests were negative, and her
additional bloodwork was normal. (Ex. 1, pp. 16-21.)

Petitioner had her next follow up appointment with Dr. Cancado on July 28, 2016,
for “polyneuropathy and bilateral carpel tunnel syndromes.” (Ex. 1, p. 72.) Petitioner
reported that her pain continued, particularly in her lower extremities, impacting her
ability to walk. (Id. at 72.) Her neurological exam revealed “unsteadiness on her feet,”
and Dr. Cancado observed that petitioner was “unable to walk on her heels and toes.”
(Id. at 73.) She was able to stand on her tiptoes, but not on her ankles. (Id.) Dr.
Cancado’s impression was polyneuropathy of unclear etiology and bilateral carpal
tunnel syndromes. (Id.) Petitioner remained on Fosamax and Amitriptyline. (Id. at 74.)

Petitioner began physical therapy on August 8, 2016. (Ex. 5, p. 222.) It was
recommended that petitioner attend physical therapy two times a week for 10 weeks.
(Id. at 222-23.) Petitioner attended physical therapy throughout August of 2016. (Id. at
207-08, 211-20.) Petitioner had a follow up appointment with Dr. Cancado on August
29, 2016, for “polyneuropathy of unclear etiology and bilateral carpal tunnel syndromes.”
(Ex. 1, p. 75.) Although physical therapy had been partially helpful, petitioner continued
to experience significant pain. (Id.) On exam, she continued to have “some degree of
imbalance,” and she could not walk on her heels but could stand on her tiptoes. (Id. at
76.)

Petitioner continued to attend physical therapy throughout September of 2016.
(Ex. 5, pp. 185-203.) On September 6, 2016, petitioner reported improvement,
particularly in her right foot and left hand. (Id. at 202.) On September 16, 2016,
petitioner had primary care appointment, during which it was noted that petitioner was in
the care of Dr. Cancado and had been diagnosed with sensorimotor neuropathy of
unknown etiology. (Ex. 2, p. 11.) Petitioner explained that her leg and back pain,
tingling, and numbness, along with a rash, had begun after a trip to California. (Id.) It
was noted that petitioner was on Fosamax for osteoporosis and hormone replacement
therapy for menopausal symptoms. (Id. at 12.) Petitioner’s hyperlipidemia was also

9
noted. (Id.) Petitioner’s physical exam revealed “[n]o bipedal edema, no cyanosis, no
clubbing,” and “peripheral pulses intact.” (Id. at 14.) However, petitioner’s straight leg
raising test was positive bilaterally. (Id.) Her primary care provider’s impression was
“[l]eft hydronephrosis without hydroureter versus multiple parapelvic cysts in the left
renal central sinus complex” and “[m]ultilevel degenerative facet joint arthropathy in the
lumbar spine, along with moderate degenerative disc disease,” as well as a retroverted
uterus and “[b]ilateral moderate upper pulmonary lobe pleural and parenchymal
scarring,” particularly on the right. (Id. at 11-12.) The assessment was sensorimotor
polyneuropathy of unknown cause, which had been progressing over the past few
months. (Id. at 14.)

On September 21, 2016, petitioner presented to Nurse Practitioner (“NP”) Caitlin
Shino for a neuromuscular evaluation of her bilateral foot tingling and gait imbalance.
(Ex. 3, pp. 12-15.) It was noted that petitioner developed “back pain and tingling in her
toes and finger tips as well as a diffuse rash of ‘red dots’ across her abdomen” within
ten days after she received a Tdap and pneumococcal vaccination. (Id. at 12.)
Petitioner’s examination revealed an “abnormal tandem gait,” that is “off balance with
[asymmetric] steppage,” specifically due to the left foot inverting. (Id. at 13-14.) Her
upper extremity strength was intact, and in her lower extremities, her proximal muscle
groups were at maximal strength. (Id. at 14.) However, her ankle dorsiflexion was 5-
/4+, inversion was 5-/5-, eversion was 5-/3, and great toe extension was 3/3. (Id.) The
record notes that “Dr. Carlson was able to come in and see [petitioner]; he reviewed the
entire history and performed an independent examination. He formulates the following
impression and plan: . . . [a]cute onset distal [asymmetric] non-length dependent
polyneuropathy most likely etiology is an acute autoimmune neuropathy associated with
tetanus vaccination.” (Id.) Additionally, it was noted that “post-vaccinal neuropathies
can develop often related to a leukocytoclastic vasculitis,” and that petitioner “had a
truncal rash associated with peripheral nerve symptomatology early in her presentation
which is likely a dermatologic comorbid condition.” (Id.) Alternative diagnoses, such as
Lyme disease or sarcoidosis, were considered and ruled out. (Id.)

Petitioner continued her physical therapy throughout October 2016. (Ex. 5, pp.
161-84.) She was reevaluated on October 6, 2016 and reported improvement. (Id. at
175.) Petitioner had a follow up appointment with Dr. Cancado on October 31, 2016.
(Ex. 1, p. 86.) He noted that her neuromuscular specialist had diagnosed her with post
vaccine polyneuropathy. (Id. at 87.) A neurological exam noted that petitioner’s
balance had improved and that she was able to stand on her tiptoes; however, she was
still unable to walk or stand on her heels. (Id.)

On November 4, 2016, petitioner presented to a new primary care provider. (Ex.
2, pp. 8-10.) She reported that she had developed a rash and bilateral tingling and pain
in her feet after receiving a Tdap vaccine on May 10, 2016. (Id. at 8.) It was further
noted that petitioner had been diagnosed with polyneuropathy that was likely caused by
her Tdap vaccine. (Id. at 8.) It was observed that petitioner had experienced mild
improvement in her neuropathic symptoms. (Id. at 10.) Petitioner continued to pursue
physical therapy throughout November 2016. (Ex. 5, pp. 149-60.) She was reevaluated

10
on November 7, 2016, and she continued to report improvement. (Id. at 159.) On
November 11, 2016, petitioner was reevaluated by NP Shino for “distal asymmetric non-
length dependent polyneuropathy most likely an acute autoimmune neuropathy
associated with tetanus vaccination.” (Ex. 3, p. 4.) Petitioner reported that her balance
and walking had improved; however, she continued to have some numbness, tingling,
and occasional pain in her feet. (Id.) Petitioner’s labs were negative for infection or
inflammation. (Id.) Petitioner’s physical exam revealed ankle dorsiflexion at 5-/4+,
inversion at 5/5, eversion at 5/5-, and great toe extension at 4-/4-. (Id. at 5.)
Additionally, petitioner’s Achilles reflexes were absent. (Id.) Petitioner’s distal power
and gait dynamics had improved. (Id.)

Petitioner continued physical therapy throughout December 2016 and January
2017. (Ex. 5, pp. 102-48.) Petitioner was reevaluated on December 5, 2016, during
which she reported that she felt like her improvement was beginning to plateau. (Id. at
140.) Petitioner was reevaluated again on January 10, 2017, and reported additional
improvement, explaining that she had “less sensation of ridges on the bottom of her
feet,” but she continued “to have pain that radiate[d] across the dorsum of her foot and
up, around the lateral ankle.” (Id. at 112.) Petitioner had a follow up appointment with
Dr. Cancado on January 26, 2017, for “peripheral neuropathy possibly related to a
tetanus shot.” (Ex. 1, p. 92.) He noted that petitioner’s condition was improving. (Id.)
Her neurological exam revealed that petitioner was able to walk on her tiptoes and that
her gait had improved; however, she was unable to walk or stand on her heels. (Id. at
93.)

Petitioner had a follow up appointment with her primary care physician on
February 8, 2017, during which she reported chronic fatigue and foot pain associated
with her neuropathy. (Ex. 2, p. 5.) It was also noted that petitioner was taking
Alendronate for her osteoporosis. (Id.) Petitioner continued her physical therapy
throughout February and March of 2017. (Ex. 5, pp. 57-101.) She was reevaluated on
February 6, 2017, where she reported that her leg pain had “eased slightly.” (Id. at 98.)
She was reevaluated again on March 3, 2017, where she reported a sharp pain in her
ankle/foot and an increased sensation of stiffness. (Id. at 75.)

On March 18, 2017, petitioner returned for a neuromuscular evaluation of her
“distal asymmetric non-length dependent polyneuropathy most likely an acute
autoimmune neuropathy associated with tetanus vaccination.” (Ex. 3, p. 1.) Petitioner
reported improvement in her balance and speed of walking; however, she continued to
complain of pain, numbness, and tingling in her feet. (Id.) It was noted that petitioner’s
HTLV-1, CRP, and ANCA labs were negative. (Id.) Her physical examination showed
normal upper extremity strength and that her “[p]roximal muscle groups in lower
extremities remain intact.” (Id. at 2.) Her ankle dorsiflexion had improved to 5/5- and
her great toe extension had improved to 5-/4+. (Id.) Her Achilles reflexes were still
absent, and her gait was “mildly off balance with poor heel strike bilaterally.” (Id.)

On May 4, 2017, petitioner had a follow up appointment with Dr. Cancado. (Ex.
1, p. 95.) He reported that petitioner’s symptoms were slowly improving. (Id.)

11
Petitioner was able to walk on her heals and tiptoes, but was unable to “do the tandem
gait.” (Id. at 96.) During a follow up primary care appointment on May 11, 2017,
petitioner reported that she was taking less of her pain medication, but her feet
remained stiff and swollen. (Ex. 2, p. 1.) It was noted that petitioner’s osteoporosis
score had worsened. (Id.) Petitioner underwent an echocardiogram on May 30, 2017,
which indicated a heart murmur. (Id. at 56-58; Ex. 7, pp. 39-42.)

On September 15, 2017, petitioner sought a second opinion on her
polyneuropathy from Dr. Michael Turner. (Ex. 6, p. 102.) Dr. Turner reported that
petitioner had “ongoing symptoms from an immune mediated polyneuropathy triggered
by tetanus vaccination in May 2016.” (Id.) Petitioner reported continued pain,
numbness, and paresthesias. (Id.) Her neurological exam revealed that she had some
numbness in her feet. (Id. at 103.) Dr. Turner recorded his impression as “[i]mmune
mediated polyneuropathy secondary to tetanus vaccination.” (Id.) He started her on
glutathione and superoxide dismutase, and he recommended a detox massage and
sauna use, along with continued vibration plate therapy. (Id. at 104.) Petitioner had a
follow up appointment with Dr. Cancado on November 2, 2017, during which he noted
that petitioner’s symptoms were improving, and petitioner was continued on
Amitriptyline. (Ex. 12, pp. 1-2.) During this visit, petitioner was able to walk on her
heals and tiptoes, as well as “the tandem gait with minimal difficulty.” (Id. at 2.)
Additionally, Dr. Cancado reported that petitioner walked with “mild unsteadiness.” (Id.)

Petitioner’s next follow up appointment with Dr. Cancado was on March 1, 2018.
(Ex. 12, p. 4.) Dr. Cancado recorded that while petitioner’s condition had significantly
improved, she experienced residual cramps in the arches and ankles,” which he
suggested could be attributed to stopping Amitriptyline. (Id. at 4-5.) Petitioner’s
neurological exam showed Tinel’s sign in both ankles and “decreased pinprick in the
plantar surfaces of both feet.” (Id. at 5.) Dr. Cancado considered peripheral neuropathy
and tarsal tunnel syndromes as possible differential diagnoses for petitioner’s continuing
symptoms. (Id.) On September 10, 2018, petitioner had another follow up appointment
with Dr. Cancado, during which it was noted that petitioner had noticed improvement in
her symptoms after restarting Amitriptyline for her peripheral neuropathy. (Id. at 7.) Her
neurological exam noted that she was able to walk on her heels and her toes and that
she had no significant ataxia. (Id. at 8.) Petitioner was continued on Amitriptyline. (Id.)

In 2019, petitioner had two follow up appointments with Dr. Cancado, one on
March 11, 2019, and another on September 30, 2019. (Ex. 15.) During the March 11,
2019 appointment, petitioner’s symptoms were improving, and she remained on
Amitriptyline. (Id. at 1.) Petitioner was able to walk on both her heels and her tiptoes.
(Id. at 2.) During her September 30, 2019 appointment, petitioner reported continued
improvement on Amitriptyline and “no weakness or significant gait disturbance.” (Id. at
4.) She remained able to walk on her heels and tiptoes. (Id. at 5.)

Petitioner continued with physical therapy from April of 2017 until January of
2019, during which she continued to report pain and stiffness in her feet that would flare
occasionally. (Ex. 5, pp. 1-56; Ex. 13.) On April 28, 2020, petitioner was evaluated by a

12
chiropractor for bilateral foot pain. (Ex. 28, p. 51.) Petitioner reported that she had
been diagnosed with peripheral neuropathy “due to what is suspected as a vaccine-
related injury.” (Id.) She reported a “dull, achy, and burning pain in her feet that is
consistent and constant.” (Id.) Her physical exam revealed a 32% total reduced range
of motion in her left ankle and a 45% total reduced range of motion in her right ankle.
(Id. at 51-52.) Her neurological exam revealed weakness in the nerve root on the motor
exam and reflex exam. (Id. at 52.) Her diagnoses were “[s]egmental and somatic
dysfunction of lower extremity,” and pain in her left and right ankle joints. (Id. at 53.)
She continued to see a chiropractor throughout the rest of 2020 for bilateral foot pain,
weakness, and stiffness. (Ex. 28.)

b. Testimony

Petitioner submitted an affidavit and testified at the hearing. (Ex. 11; Tr. 9-45.)
Petitioner testified that she received the Prevnar 13 and Tdap vaccines on May 10,
2016. (Ex. 11, ¶ 4.) She explained that, after a few days, she broke out into a rash.
(Id. ¶ 5.) Roughly 10 days after receiving the vaccine, petitioner developed joint pain,
numbness and tingling in her hands and feet, difficulty sleep, and “a general sensation
of not feeling well.” (Id. ¶ 6.) Although she has recovered some of her function, she still
experiences some pain and flare ups when she is on her feet for an extended period of
time. (Id. ¶¶ 26-28.) Petitioner explained that, before she received the tetanus vaccine,
she was involved with her grandchildren and her church, and she “loved piecing and
quilting quilts for foster children.” (Id. ¶ 32.) However, after she received the tetanus
vaccine, she had trouble “walking, climbing stairs, bending over to pick up things, lifting
small items, sitting, sleeping, and paying attention because the pain was so distracting.”
(Id. ¶ 33.) Petitioner still experiences “cramps and pain in [her] feet and ankles,” and
she continues to undergo physical therapy, take supplements, and follow up with her
physicians. (Id. ¶ 37.)

IV. Summary of Expert Opinions

a. Petitioner’s Neurologist, Alberto A. Martinez-Arizala, M.D.

Petitioner’s expert, Dr. Alberto A. Martinez-Arizala, submitted three expert reports
in this case and testified at the entitlement hearing. (Exs. 16, 29, 42; Tr. 46-108, 239-
52.) He was proffered without objection as an expert in neurology.4 (Tr. 51.) Dr.
4 Dr. Alberto A. Martinez-Arizala received his bachelor’s degree from Florida State University and his

medical degree from the University of Miami School of Medicine. (Ex. 17, p. 1.) He completed an
internship in categorial medicine at Walter Reed Army Medical Center and a residency in neurology at
Letterman Army Medical Center. (Id.) He is board certified in neurology. (Id. at 2.) Dr. Martinez-Arizala
currently works as the Director of the Spine Division and a professor of clinical neurology, neurosurgery,
and physical therapy in the Department of Neurology at the University of Miami. (Id.; Ex. 16, p. 1.) He is
also the principal investigator for the Miami Project to Cure Paralysis at the University of Miami. (Ex. 17,
p. 2.) He was also the Chief of Spinal Cord Injury Service at the Miami VA Health Care System, where he
treated patients with spinal cord disorders, multiple sclerosis, and peripheral neuropathies resulting in
severe paralysis. (Ex. 16, p. 1.) He has published eight books and monographs, over 30 juried or
refereed journal articles and exhibitions, and over 50 other works, publications, and abstracts. (Ex. 17,
pp. 3-10.)

13
Martinez-Arizala opined that petitioner suffered an autoimmune polyneuropathy (Ex. 16,
p. 5; Tr. 52) and, more specifically, based on her electrodiagnostic study of July 1, 2016,
a moderate to severe axonal sensory and axonal and demyelinating motor neuropathy,
which he described as “mostly” axonal. (Tr. 59-60, 68 (discussing Ex. 1, p. 1).) He
further opined that petitioner’s neuropathy, the onset of which began about two weeks
post-vaccination, can be associated with her tetanus vaccination, which he asserts is
consistent with the opinion of the treating physician, Dr. Carlson. (Ex. 16, pp. 5, 7; Tr.
55, 71-72, 83-84.)

Dr. Martinez-Arizala stressed that other possible causes of peripheral
neuropathy, including infections, diabetes, vitamin deficiencies, and thyroid disorders,
were ruled out in petitioner’s case. (Ex. 16, pp. 5, 7.) Contrary to Dr. Donofrio, he does
not agree that petitioner was suffering from a urinary tract infection prior to onset of her
condition.5 (Tr. 73, 90-91, 244-45.) Although he acknowledged that petitioner’s
urinalysis had some markers of infection, he stressed that she was asymptomatic, never
treated for a urinary tract infection, and that her urine sample was contaminated. (Id.)
Dr. Martinez-Arizala acknowledged that petitioner’s tests for some autoimmune
disorders were negative; however, he explained that “negative results exclude these
specific diseases, but not all autoimmune diseases.” (Ex. 29, p. 1.) In addition,
although petitioner’s lab results did not show any evidence of acute inflammation, the
inflammatory markers CRP and ESR “are not usually elevated . . . in autoimmune
neuropathies.” (Id. at 3 (citing Yosria A. Altaweel et al., Correlative Study Between C-
Reactive Protein, Clinical Severity, and Nerve Conduction Studies in Guillain-Barré
Syndrome, 54 EGYPTIAN J. NEUROLOGY PSYCHIATRY & NEUROSURGERY 1 (2018) (Ex. 38);
Chetana Vaishnavi et al., C-Reactive Protein in Patients with Guillain Barré Syndrome,
57 INDIAN J. PATHOLOGY & MICROBIOLOGY 51 (2014) (Ex. 39)); Ex. 42, p. 1 (citing G.
Sivaram Naik et al., Anti-Ganglioside Antibodies Profile in Guillain-Barré Syndrome:
Correlation with Clinical Features, Electrophysiological Pattern, and Outcome, 65
NEUROLOGY INDIA 1001 (2017) (Ex. 43); Jiting Zhu et al., Anti-Ganglioside Antibodies in
Guillain-Barre Syndrome: A Novel Immunoblotting-Panel Assay, 12 FRONTERS
NEUROLOGY 1 (2021) (Ex. 44)).) Dr. Martinez-Arizala also acknowledged that
petitioner’s MRI scans did not show enhancing signals in the nerve roots; however,
“autoimmune neuropathies can be associated with enhancement of the cauda equina
nerves and roots on MRI, but this is not always present.” (Ex. 29, p. 1 (citing Kenneth
C. Gorson et al., Prospective Evaluation of MRI Lumbosacral Nerve Root Enhancement
in Acute Guillain-Barré Syndrome, 47 NEUROLOGY 813 (1996) (Ex. 34)).)

Further, Dr. Martinez-Arizala noted that, while the EMG data did suggest
petitioner’s neuropathy was axonal, autoimmune peripheral neuropathies can be
axonal. (Ex. 29, p. 2 (citing T.E. Feasby et al., An Acute Axonal Form of Guillain-Barré
Polyneuropathy, 109 BRAIN 1115 (1986) (Ex. 35); R. Omdal et al., Peripheral
Neuropathy in Systemic Lupus Erythematosus – A Longitudinal Study, 103 ACTA

5 Initially, Dr. Martinez-Arizala disputed that urinary tract infections have been shown to cause peripheral

neuropathies. (Ex. 29, p. 2.) However, he ultimately conceded that it can happen, albeit rarely. (Ex. 42,
p. 1; Tr. 91-92.)

14
NEUROLOGICA SCANDINAVICA 386 (2001) (Ex. 36); Lasse G. Gøransson et al., Small-
Diameter Nerve Fiber Neuropathy in Systemic Lupus Erythematosus, 63 ARCHIVES
NEUROLOGY 401 (2006) (Ex. 37)); Ex. 42, pp. 2-3.) As an example, Dr. Martinez-Arizala
explained that the acute motor axonal neuropathy variant of GBS has been associated
with infections, such as Camplobacter jejuni (“C. jejuni”), flu, SARS-CoV-2, and
Hepatitis A, as well as the flu and COVID-19 vaccines. (Ex. 42, pp. 2-3 (citing Charlene
Hafer-Macko et al., Acute Motor Axonal Neuropathy: An Antibody-Mediated Attack on
Axolemma, 40 ANNALS NEUROLOGY 635 (1996) (Ex. 54); Marko Kutleša et al., Acute
Motor Axonal Neuropathy Associated with Pandemic H1N1 Influenza A Infection, 13
NEUROCRITICAL CARE 98 (2010) (Ex. 55); Alireza Samadi et al., A 30-Year-Old Man with
Acute Motor Axonal Neuropathy Subtype of Guillain-Barré Syndrome Having Hepatitis A
Viral Infection, 11 MIDDLE E.J. DIGESTIVE DISEASES 110 (2019) (Ex. 56); Fabio Giuseppe
Masuccio et al., A Rare Case of Acute Motor Axonal Neuropathy and Myelitis Related to
SARS-CoV-2 Infection, 268 J. NEUROLOGY 2327 (2021) (Ex. 57); T. Bueso et al.,
Guillain-Barre Syndrome and COVID-19: A Case Report, 200 CLINICAL NEUROLOGY &
NEUROSURGERY 106413 (2021) (Ex. 58); Nihal Akçay et al., Axonal Guillain-Barre
Syndrome Associated with SARS-CoV-2 Infection in a Child, 93 J. MED. VIROLOGY 5599
(2021) (Ex. 59); Catherine Jordan et al., Guillain-Barre Syndrome-Acute Motor Axonal
Neuropathy as Neurologic Sequela in a COVID-19 Critically-Ill Patient: A Case Report,
26 Respirology 177 (2021) (Ex. 60); Fulvio A. Scorza & Josef Finsterer, Asymptomatic
SARS-CoV-2 Infection Complicated by Acute, Motor and Sensory, Axonal Neuropathy
(AMSAN), CLINICAL NEUROLOGY & NEUROSURGERY, Oct. 2021, at 1 (Ex. 61); Cristina
Petrelli et al., Acute Motor Axonal Neuropathy Related to COVID-19 Infection: A New
Diagnostic Overview, 22 J. CLINICAL NEUROMUSCULAR DISEASE 120 (2020) (Ex. 62);
Nozomu Sato et al., Acute Transverse Myelitis and Acute Motor Axonal Neuropathy
Developed After Vaccinations Against Seasonal and 2009 A/H1N1 Influenza, 50
INTERNAL MED. 503 (2011) (Ex. 63); Vikas Dalwadi et al., Axonal-Variant Guillain-Barre
Syndrome Temporally Associated with mRNA-Based Moderna SARS-CoV-2 Vaccine,
13 CUREUS e18291 (2021) (Ex. 64); Antonina Luca et al., Pure Sensitive Chronic
Inflammatory Axonal Polyneuropathy Following Pfizer COVID-19 Vaccine, 43
NEUROLOGICAL SCIS. 1431 (2022) (Ex. 65); Zachary P. Morehouse et al., A Rare Variant
of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination, 13 CUREUS e18153
(2021) (Ex. 66); Nurhan Kaya Tutar et al., A Variant of Guillain-Barre Syndrome After
SARS-COV-2 Vaccination: AMSAN, 74 IDEGGYOGY SZ. 286 (2021) (Ex. 67)).)

Dr. Martinez-Arizala also noted that petitioner was diagnosed with
leukocytoclastic vasculitis, “an immune mediated vasculitis, which has been reported in
association with influenza and tetanus vaccination.” (Ex. 29, p. 1 (citing Stella X. Chen
& Philip R. Cohen, Cutaneous Leukocytoclastic Vasculitis Following Influenza
Vaccination in Older Adults: Report of Bullous Purpura in an Octogenarian After
Influenza Vaccine Administration, 10 CUREUS e2323 (2018) (Ex. 30); Seena Monjazeb
et al., A Case of Leukocytoclastic Vasculitis Following Influenza Vaccination, 2 JAAD
CASE REPS. 340 (2016) (Ex. 31); Sissi Cao & Dongmei Sun, Leucocytoclastic Vasculitis
Following Influenza Vaccination, 2017 BMJ CASE REPS. J. 1 (Ex. 32); Liviana Da Dalt et
al., Henoch-Schönlein Purpura and Drug and Vaccine Use in Childhood: A Case-
Control Study, 42 ITALIAN J. PEDIATRICS 60 (2016) (Ex. 33)).) Though respondent’s

15
experts suggested that vasculitis is itself a known cause of neuropathies, Dr. Martinez-
Arizala suggested that the leukocytoclastic vasculitis would be a separate, comorbid
reaction to vaccination. (Ex. 42, pp. 3-4; Tr. 71-72, 92-93.) Moreover, he felt that the
presence of the purported leukocytoclastic vasculitic event added further support to the
notion that petitioner’s post-vaccination clinical course was consistent with an immune-
mediated process. (Tr. 63.) Skin biopsies are often used to confirm leukocytoclastic
vasculitis, but Dr. Martinez-Arizala opined that “diagnosis can be strongly suggested by
the history, physical examination, clinical course, and laboratory tests.” (Ex. 42, p. 3.)
Ultimately, however, he conceded that petitioner’s rash “could have been anything,”
though he maintained that the timing at least raises a question as to whether it
represented a post-vaccination vasculitis. (Tr. 252; see also id. at 71-72, 92-93.)
Although respondent had raised that petitioner’s neuropathy did not respond to the
course of steroids she received for her rash, Dr. Martinez-Arizala explained that while
steroids can be effective in treatment of autoimmune neuropathies, “they are not used
for acute neuropathies.” (Ex. 29, p. 3.)

Dr. Martinez-Arizala’s theory of how vaccines cause autoimmune disorders is
based on molecular mimicry, which is “where components of the vaccine possess
sequence similarities between it and specific human proteins that results in the cross-
activation of autoreactive T or B cells.” (Ex. 16, p. 5.) He explained further that this
cross reactivity “causes a reaction of the immune system against the pathogenic
antigens that may harm the similar human proteins, essentially causing autoimmune
disease.” (Id. (citing Yahel Segal & Yehuda Shoenfeld, Vaccine-Induced Autoimmunity:
The Role of Molecular Mimicry and Immune Crossreaction, 15 CELLULAR & MOLECULAR
IMMUNOLOGY 586 (2018) (Ex. 18); Javaraiah Srinivasappa et al., Molecular Mimicry:
Frequency of Reactivity of Monoclonal Antiviral Antibodies with Normal Tissues, 57 J.
VIROLOGY 397 (1986) (Ex. 19)); see also Robert S. Fujinami & Michael B.A. Oldstone,
Amino Acid Homology Between the Encephalitogenic Site of Myelin Basic Protein and
Virus: Mechanism for Autoimmunity, 230 SCIENCE 1043 (1985) (Ex. 74); Anand M.
Gautam et al., A Polyalanine Peptide with Only Five Native Myelin Basic Protein
Residues Induces Autoimmune Encephalomyelitis, 176 J. EXPERIMENTAL MED. 605
(1992) (Ex. 75); Lawrence Steinman, Autoimmune Disease, 269 SCI. AM. 106 (1993)
(Ex. 76).) Dr. Martinez-Arizala listed the increase in GBS following swine flu vaccination
as an example of autoimmune peripheral neuropathy related to vaccination, where there
is also additional evidence that molecular mimicry was the link between the disease and
vaccination. (Ex. 16, p. 6 (citing Segal & Shoenfeld, supra, at Ex. 18; Irving Nachamkin
et al., Anti-Ganglioside Antibody Induction by Swine (A/NJ/1976/H1N1) and Other
Influenza Vaccines: Insights into Vaccine-Associated Guillain-Barré Syndrome, 198 J.
INFECTIOUS DISEASES 226 (2008) (Ex. 21; see also Ex. 53)).)

As it pertains to the Tdap vaccine at issue in this case, Dr. Martinez-Arizala cited
several case reports “of peripheral neuropathies related to the administration of the
tetanus vaccine.” (Ex. 16, p. 6 (citing Kannikar Kongbunkait et al., Clinical
Manifestations and Outcomes of Guillain-Barré Syndrome After Diphtheria and Tetanus
Vaccine (dT) During a Diphtheria Outbreak in Thailand: A Case Series, 19 NEUROLOGY
ASIA 137 (2014) (Ex. 22) (reporting four cases of patients who developed GBS between

16
four weeks and four months after receiving the diphtheria and tetanus vaccine during a
diphtheria outbreak in Thailand); Hussam Ammar, Guillain-Barré Syndrome After
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine: A Case
Report, 5 J. MED. CASE REPS. 502 (2011) (Ex. 23) (reporting one case of GBS just over
one week following a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis
vaccine); W. Baust et al., Peripheral Neuropathy After Administration of Tetanus Toxoid,
222 J. NEUROLOGY 131 (1979) (Ex. 24) (reporting the case of a patient who developed
peripheral neuropathy three weeks after receiving a tetanus toxoid vaccination); George
I. Blumstein & Harold Kreithen, Peripheral Neuropathy Following Tetanus Toxoid
Administration, 198 JAMA 1030 (1966) (Ex. 25) (reporting a case of a patient who
developed a fever, rash, and motor and sensory paralysis within 24 hours of receiving a
tetanus toxoid vaccine, and was eventually diagnosed with peripheral neuropathy);
Leon Reinstein et al., Peripheral Neuropathy After Multiple Tetanus Toxoid Injections,
63 ARCHIVES PHYSICAL MED. & REHAB. 332 (1982) (Ex. 26) (reporting the case of a
patient who received three tetanus toxoid vaccines within five months and developed
occasional numbness of the feet 24 hours after the first shot, as well as sensorimotor
polyneuropathy roughly six weeks after his final vaccination); Ute Quast et al., Mono-
and Polyneuritis After Tetanus Vaccination (1970-1977), 43 INT’L SYMP. IMMUNIZATION 25
(1979) (Ex. 27) (reporting 22 cases of neuritis between three hours and two weeks
following tetanus toxoid vaccination)).)

Finally, with regard to timing, Dr. Martinez-Arizala explained that petitioner
developed symptoms less than two weeks following her tetanus vaccination. (Ex. 16, p.
7.) Dr. Martinez-Arizala opines that this timeline “is quite consistent with the literature.”
(Id.) He also opined that petitioner’s leukocytoclastic vasculitis developed 10 days after
vaccination, which “fits what has been reported in the literature and the time it is
generally accepted for the body to mount an abnormal immune response.” (Ex. 42, p.
4.)

b. Respondent’s Expert, Peter D. Donofrio, M.D.

Respondent’s first expert, Dr. Peter D. Donofrio, provided three expert reports
and testified during the entitlement hearing. (Exs. A, E, G; Tr. 109-61.) During the
hearing, he was proffered without objection as an expert in nerve and muscular
disorders, as well as electrodiagnostic medicine.6 (Tr. 114.) Stressing that there are
over 100 known causes of peripheral neuropathies (Id. at 115-16), Dr. Donofrio
6 Dr. Peter D. Donofrio received his medical degree from Ohio State University School of Medicine. (Ex.
B, p. 1.) From there, he completed two residencies, one in internal medicine at Good Samaritan Hospital
and another in neurology at the University of Michigan Medical Center. (Id. at 2.) Additionally, he
completed a neuromuscular fellowship at the University of Michigan. (Id.) He is board certified in internal
medicine, psychiatry and neurology, electro diagnostic medicine, and neuromuscular medicine. (Id.; Ex.
A, p. 1.) He currently works as the Vice-Chair of Clinical Affairs in the Department of Neurology, as a
professor of neurology, and as the Director of the Neuromuscular Division at Vanderbilt University School
of Medicine. (Ex. B, p. 1; Ex. A, p. 1.) He has experience evaluating “a spectrum of neuropathies such
as Guillain-Barre Syndrome (GBS) and CIDP and the related condition of Miller Fisher Syndrome (MFS).”
(Ex. A, p. 1.) He has published over 100 journal articles, in addition to one textbook, and over 100 book
chapters and abstracts. (Ex. B, pp. 13-32; Ex. I, pp. 13-32.)

17
highlighted the lack of laboratory support for an autoimmune etiology for petitioner’s
condition. (Ex. A, p. 7.)

Specifically, Dr. Donofrio noted that petitioner underwent testing for several
autoimmune conditions and antibodies, none of which could be confirmed. (Ex. A, p. 7.)
While Dr. Donofrio does acknowledge that “negative antibody studies do not rule out all
autoimmune diseases,” he still maintained that “[i]t is hard to justify the use of the term
auto-immune without any supportive evidence.” (Ex. E, p. 1.) Additionally, petitioner’s
MRI scans “did not show enhancing signals in the nerve roots, another abnormality that
would support the concept of an auto-immune neuropathy,” which can be a sign of
autoimmune neuropathies, such as GBS, though he emphasizes that petitioner was not
diagnosed with GBS. (Ex. A, pp. 7-8; Ex. E, p. 1.) He also noted that petitioner did not
undergo a spinal tap or nerve biopsy, both of which would have aided in the diagnosis
of an autoimmune neuropathy. (Ex. A, p. 7.) Dr. Donofrio further noted of petitioner’s
electrodiagnostic studies that, “[e]ven though the two sets of nerve conduction studies
were described as demyelinating, analysis of the raw data suggests an axonal loss
process rather than a demyelinating one.” (Id. at 8 (citing Joint Task Force of the EFNS
and the PNS, European Federation of Neurological Societies/Peripheral Nerve Society
Guideline on Management of Chronic Inflammatory Demyelinating
Polyradiculoneuropathy: Report of a Joint Task Force of the European Federation of
Neurological Societies and the Peripheral Nerve Society – First Revision, 15 J.
PERIPHERAL NERVOUS SYS. 1 (2010) (Ex. A, Tab 1)).) Dr. Donofrio opined that this would
leave an inflammatory autoimmune condition less likely, though he acknowledged that
axonal neuropathies can be autoimmune. (Tr. 127-29; Ex. G, p. 1.) Dr. Donofrio also
noted briefly that petitioner’s leukocytoclastic vasculitis diagnosis was based on clinical
features alone, while “[d]ocumentation of vasculitis of peripheral nerve would require a
biopsy of an involved peripheral nerve.” (Ex. E, p. 1; Ex. G, pp. 2-3.) Dr. Donofrio
contends that because petitioner did not have a biopsy nor did she meet all the criteria
for classification of hypersensitivity vasculitis (leukocytoclastic vasculitis), she did not
have an autoimmune vasculitis. (Ex. G, p. 2.) He did acknowledge during the hearing,
however, that a biopsy would not be a realistic expectation in clinical practice. (Tr. 145-
46.)

Dr. Donofrio also explained that, if petitioner’s condition is autoimmune, other
possible explanations for petitioner’s condition are a urinary tract infection that petitioner
was diagnosed with on May 2, 2016, or a viral exanthem evidenced by petitioner’s
rash.7 (Ex. A, p. 8 (citing Ex. 4, p. 51).) He explained that “[t]he same hypothesis for

7 Dr. Donofrio’s opinion on this point is harder to understand following the hearing. While he consistently
distinguished the idea of holding an opinion that petitioner’s neuropathy was an autoimmune reaction to
an infection from the idea of holding the opinion that autoimmunity stemmed from her vaccination (Tr.
130-31), he also ultimately agreed that he believes a urinary tract infection more likely than not caused
petitioner’s neuropathy (Id. at 157-59), a conclusion which would also necessarily mean that an
autoimmune etiology was more likely than not (Id. at 131 (agreeing that if the court accepts his testimony
doubting the presence of autoimmunity, then the infection would be an unlikely cause)). Taking Dr.
Donofrio’s opinion as a whole (both his reports and his complete testimony), he seems to be opining that,
even in the absence of clinical indicators of autoimmunity, patient history can still potentially be
informative of the etiology of a polyneuropathy. However, based on this patient’s history, her proposed

18
molecular mimicry would apply to the antigen of the agent causing the UTI.”8 (Id.) Dr.
Donofrio also alternatively suggested that petitioner’s joint pain, back pain, swollen
joints, stiffness, and sensory motor defects could be evidence of a rheumatologic
condition, which have been associated with peripheral neuropathy. (Id. (citing Haatem
Reda & Russell L. Chin, Peripheral Neuropathies of Rheumatologic Disease and
Gluten-Related Disorders, 34 SEMINARS NEUROLOGY 413 (2014) (Ex. A, Tab 2)).)

Regarding petitioner’s theory, Dr. Donofrio noted that petitioner cited several
pieces of medical literature on the association between the tetanus vaccine and GBS,
and a single case report of radial nerve palsy and brachial plexopathy after tetanus
vaccination. (Ex. A, p. 9.) He observed, however, that petitioner has not been
diagnosed with GBS, and opined that “petitioner’s expert did not discuss a medical
theory as to how the Tdap vaccine or the Prevnar vaccine or the combination of the two
caused her polyneuropathy.” (Id.) He noted that the Institute of Medicine “does not
have a section on tetanus vaccination and peripheral neuropathy.”9 (Id.) Dr. Donofrio
also suggested that, because petitioner’s expert described petitioner’s vasculitis as “skin
isolated small vessel vasculitis . . . not associated with peripheral neuropathies,”
petitioner’s expert ruled out “any association of the petitioner’s polyneuropathy with the
skin isolated vessel vasculitis as the polyneuropathy would represent a second organ
system.” (Ex. G, p. 3.) Dr. Donofrio explained that, even if petitioner’s rash was
temporally related to her vaccination, “petitioner could easily have developed a rash
from other causes.” (Id.)

c. Respondent’s Expert, Penelope A. Morel, M.D.

Respondent’s second expert, Dr. Penelope Morel, submitted three expert reports
and testified at the hearing in this case. (Exs. C, F, H; Tr. 164-238.) During the hearing

urinary tract infection, but not her vaccination, could be so informative. Under this logic, the presence of
an identifiable autoimmune trigger contributes to the overall conclusion that autoimmunity is a likely
etiology. Thus, even having concluded that a urinary tract infection is not preponderantly supported (see
note 19, infra), I do not take Dr. Donofrio to be conceding that petitioner’s condition is autoimmune.

8 Urinary tract infections are commonly due to bacteria, which “have antigens that can lead to auto-

immune responses.” (Ex. E, p. 1.) For example, “the most common precipitating infection for GBS is
campylobacter jejuni, a bacterial infection of the gut.” (Id.) Dr. Donofrio stated that, because a urine
culture was not ordered, he could not identify the cause of petitioner’s UTI and could not, therefore,
“comment on antigens in the organism that may have precipitated an auto-immune process.” (Ex. G, pp.
1-2.) However, as further support of his conclusion that petitioner’s condition could have been caused by
her UTI, he cited several pieces of medical literature. (Id. (citing Yoon-Sik Jo et al., Recurrent Guillain-
Barré Syndrome Following Urinary Tract Infection by Escherichia coli, 33 J. KOREAN MED. SCI. e29 (2018)
(Ex. G, Tab 2); Yuriko Kono et al., Rapidly Progressive Guillain-Barré Syndrome Following Escherichia
coli Infection, 46 INTERNAL MED. 589 (2007) (Ex. G, Tab 3); Aaron Fischer & Juan Avila, Guillain-Barré
Syndrome Following an Extended-Spectrum Beta-Lactamase Escherichia coli Urinary Tract Infect: A
Case Report, 13 CUREUS e19673 (2021) (Ex. G, Tab 4); Wisit Cheungpasitporn et al., Association
Between Acute Urinary Retention and Guillain-Barré Syndrome, 29 AM. J. EMERGENCY MED. 373 (2012)
(Ex. G, Tab 5)).)
9 Referring to the IOM’s 2012 report later filed as Court Exhibit II.

19
she was proffered without objection as an excerpt in immunology.10 (Tr. 166.) Although
she acknowledged that “several polyneuropathies have an immune etiology” (Ex. C, p. 3
(citing Marinos C. Dalakas, Pathogenesis of Immune-Mediated Neuropathies, 1852
BIOCHIMICA ET BIOPHYSICA ACTA 658 (2015) (Ex. C, Tab 1))), Dr. Morel opined that such
conditions are well defined, and petitioner has not been diagnosed with any of them (Tr.
169-71).

Some immune mediated neuropathies, like GBS, are associated with “antibodies
generated to neuronal structures,” while others, such as MS or CIDP, “are associated
with immune cell infiltrates and histopathological analysis will reveal the accumulation of
immune cells, such as T cells or macrophages, in the area of demyelination.” (Ex. C, p.
1 (citing Dalakas, supra, at Ex. C, Tab 1; John A. Goodfellow & Hugh J. Willison,
Antiganglioside, Antiganglioside-Complex, and Antiglycolipid-Complex Antibodies in
Immune-Mediated Neuropathies, 29 CURRENT OP. NEUROLOGY 572 (2016) (Ex. C, Tab
2); Hugh J. Willison et al., Guillain-Barré Syndrome, 388 LANCET 717 (2016) (Ex. C, Tab
3); Jolien Wolbert et al., Deciphering Immune Mechanisms in Chronic Inflammatory
Demyelinating Polyneuropathies, 5 JCI INSIGHT e132411 (2020) (Ex. C, Tab 4)).)
Additionally, some immune mediated neuropathies include vasculitis, during which “the
inflammatory response is directed to the vessels that supply the nerves.” (Id. at 3 (citing
Michael P. Collins & Robert D. Hadden, The Nonsystemic Vasculitic Neuropathies, 13
NATURE 302 (2017) (Ex. C, Tab 5); S.H.B. Hawke et al., Vasculitic Neuropathy: A
Clinical and Pathological Study, 114 BRAIN 2175 (1991) (Ex. C, Tab 6); Linda R. Watkins
& Steven F. Maier, Neuropathic Pain: The Immune Connection, 12 PAIN, March 2004
(Ex. C, Tab 7)).) Dr. Morel explained that, generally, immune polyneuropathies are
“responsive to immune-modulating therapies,” and “will have some evidence of an
aberrant immune response in the form of evidence of systemic inflammation, . . . . the
presence of circulating auto-antibodies[,] and/or immune infiltrates in the relevant
regions.” (Id. (citing Wolbert et al., supra, at Ex. C, Tab 4; Helmar C. Lehmann et al.,
Pathogenesis and Treatment of Immune-Mediated Neuropathies, 2 THERAPEUTIC
ADVANCES NEUROLOGICAL DISORDERS 261 (2009) (Ex. C, Tab 8)).)

In petitioner’s case, however, Dr. Morel explained that “potential causes of
immune-mediated pain were investigated” yet “none of these tests supported the notion
that her polyneuropathy was caused by the immune system.” (Ex. C, p. 3.) Specifically,

10 Dr. Penelope A. Morel received her Bachelor of Medicine degree from the University of Southampton

Medical School in the United Kingdom in 1979 and her Doctor of Medicine degree from the University of
Geneva in Switzerland in 1983. (Ex. D, p. 1.) She completed three fellowships, one at the Scripps Clinic
and Research Foundation in 1985, one in immunology at Stanford University Medical Center in 1987, and
one at the University of Pittsburg Cancer Institute in 1989. (Id. at 2.) She currently works as an affiliate
member at the Center for Vaccine Research and University of Pittsburgh Cancer Institute, as well as a
professor in the Department of Immunology and the Division of Rheumatology at the University of
Pittsburgh. (Id. at 2-3.) Her research focuses on the field of autoimmunity. (Ex. C, p. 1.) Specifically,
she has “examined genetic predispositions in various human rheumatological conditions, focusing on
HLA and FcR alleles,” and she has focused on “how autoimmunity is initiated and how to design
therapies that would restore peripheral tolerance.” (Id.) She has published 70 refereed articles; 38
articles, chapters, and reviews; and 95 abstracts. (Ex. D, pp. 4-21; Ex. C, p. 1.)

20
[t]here was no evidence for any auto-antibody production and the CRP and
ESR levels were consistently low. No biopsies were performed and so it is
not possible to determine whether immune infiltrates were present.
Electrophysiological tests were compatible with a combined sensory and
motor demyelinating neuropathy. In addition, [petitioner] was extensively
investigated for rheumatoid arthritis, fibromyalgia, systemic lupus
erythematosus and other autoimmune disorders but all tests were negative.

(Id.)

Dr. Morel explained that a biopsy would have been required for a definitive
diagnosis, but one was not performed. Nonetheless, if petitioner was suffering from an
immune mediated polyneuropathy, “there would have been evidence of inflammation,
either locally or systemically,” resulting in elevated levels of CRP or ESR. (Ex. H, p. 1;
Ex. F, p. 1.) While Dr. Morel acknowledged that these would not be elevated in patients
with GBS, “[e]levated CRP and ESR are seen in situations of ongoing acute or chronic
inflammation, such as chronic inflammatory demyelinating polyneuropathy, systemic
autoimmune diseases, and other causes of immune-mediated polyneuropathy.” (Ex. F,
p. 1.) Other possible signs of inflammation include elevated WBCs, presence of auto-
antibodies, biopsy evidence of immune cell infiltration, and response of symptoms to
anti-inflammatory treatment. (Ex. H, p. 1.) There is no evidence of any of these in
petitioner’s records. (Id.) Therefore, without evidence of inflammation, it is “not
possible to conclude that an autoimmune response was responsible for the
polyneuropathy that she experienced.” (Ex. F, p. 1.) Therefore, Dr. Morel opined that
petitioner suffered from idiopathic polyneuropathy. (Ex C, p. 4.)

Dr. Morel also noted that petitioner did develop “a rash at the onset of her illness
that resolved following a short course of steroids.” (Ex. C, p. 3.) She explained that
while petitioner’s rash resolved after the steroids, her neuropathy did not, “casting doubt
on an inflammatory cause for her symptoms.” (Id. at 3-4.) She notes that petitioner’s
expert opines that petitioner’s rash was caused by leukocytoclastic vasculitis and cited
case reports in which Henoch-Schonlein purpura was preceded by a DTaP vaccination.
(Ex. H, p. 1 (citing Sara De Nitto et al., Henoch-Schonlein Purpura Following Anti
Diphtheria, Tetanus, Acellular Pertussis and Inactivated Polio (DTaP-IPV) Vaccine: A
Case Report, 12 ANNALS CASE REPS. 264 (2019) (Ex. 69); Bindu Nair et al.,
Leukocytoclastic Vasculitis Following DPT Vaccination, 18 TROPICAL J. MED. RSCH. 1
(2015) (Ex. 70)).) However, Dr. Morel explained that these cases “were characterized
by an increased WBC count, fever and evidence of inflammation.” (Id. at 1-2.) By
contrast, she noted that petitioner’s rash “was described as acute dermatitis and did not
appear to have the clinical characteristics of either [leukocytoclastic vasculitis] or
[Henoch-Schonlein purpura], and was not associated with increased WBC count or
fever.” (Id. at 2.) Dr. Morel noted further that, even after petitioner’s diagnosis of acute
inflammatory polyneuropathy, petitioner “was not treated with the standard of care for
such a condition.” (Ex. C, p. 4 (citing Wolbert et al., supra, at Ex. C, Tab 4; Lehmann et
al., supra, at Ex. C, Tab 8); Ex. F, pp. 1-2.)

21
Regarding petitioner’s theory of causation, Dr. Morel acknowledged that there
are case reports linking the GBS to vaccination but opined that only a causal
relationship with the flu vaccine has been documented. (Ex. C, p. 4 (citing Lawrence B.
Schonberger et al., Guillain-Barre Syndrome Following Vaccination in the National
Influenza Immunization Program, United States, 1976-1977, 110 AM. J. EPIDEMIOLOGY
105 (1979) (Ex. C, Tab 9)).) Instead, Dr. Morel noted that a large study found no
association between GBS and the tetanus vaccine. (Id. (citing Jessica Tuttle et al., The
Risk of Guillain-Barré Syndrome After Tetanus-Toxoid—Containing Vaccines in Adults
and Children in the United States, 87 AM. J. PUBLIC HEALTH 2045 (1997) (Ex. C, Tab
10)); Ex. F, p. 2.) Although there are case reports suggesting that GBS or CIDP
followed tetanus vaccination, Dr. Morel explained that some of these case reports were
reported prior to 1985 (Baust et al., supra, at Ex. 24; Blumstein & Kreithen, supra, at Ex.
25; Reinstein et al., supra, at Ex. 26; Quast et al., supra, at Ex. 27), and several
described cases that occurred after multiple vaccinations (Baust et al., supra, at Ex. 24;
Reinstein et al., supra, at Ex. 26). (Ex. C, p. 4.) She also noted that several cases
included patients who were treated successfully with IVIG. (Id. (citing Kongbunkait et
al., supra, at Ex. 22; Ammar, supra, at Ex. 23; Karissa L. Gable et al., Distal Acquired
Demyelinating Symmetric Neuropathy After Vaccination, 14 J. CLINICAL NEUROMUSCULAR
DISEASE 117 (2013) (Ex. C, Tab 11).)

Both genetic and environmental factors, including viral infections, contribute to
the development of autoimmunity. (Ex. C, p. 5 (citing Maria K. Smatti et al., Viruses and
Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms, 11
VIRUSES 762 (2019) (Ex. C, Tab 12)).) Thus, Dr. Morel explained that “molecular
mimicry has been around for a long time as a way to explain how infections may
precipitate autoimmune diseases.” (Id.) In this context, “an appropriate immune
response is mounted to a pathogen resulting in the generation of pathogen-specific T
cells and antibodies,” which then “may cross react on self-proteins and thereby initiate
autoimmunity.” (Id.) She explained that this hypothesis has been difficult to prove;
however, “[o]ne of the best examples of molecular mimicry is GBS which is usually
preceded by an infection of the respiratory or gastrointestinal tract,” which led “to the
development of antibodies that target peripheral nerve gangliosides and lead to axonal
damage and nerve conduction defects.” (Id. (citing Yhojan Rodríguez et al., Guillain-
Barré Syndrome, Transverse Myelitis and Infectious Diseases, 15 CELLULAR &
MOLECULAR IMMUNOLOGY 547 (2018) (Ex. C, Tab 13)).) This is the same theory by which
the flu vaccine has been implicated in causing GBS. (Id. (citing Schonberger et al.,
supra, Ex. C, Tab 9).)

Dr. Morel stressed that “[t]emporal association with vaccination does not prove
that a vaccine caused a condition; evidence substantiating that an immune process is
responsible for the disease should also be present.” (Ex. C, p. 5.) She opined that
petitioner did not have any of this substantiating evidence, therefore “there appears to
be very little evidence that the pain and neurological symptoms experienced by
[petitioner] were immune mediated.” (Id.)

22
V. Analysis

a. Althen prong one

Under Althen prong one, petitioner must provide a “reputable medical theory,”
showing that the subject vaccine can cause the type of injury alleged. Pafford v. Sec’y
of Health & Human Servs., 451 F.3d 1352, 1355-56 (Fed. Cir. 2006) (quoting Pafford v.
Sec’y of Health & Human Servs., No. 01-0165V, 2004 WL 1717359, at *4 (Fed. Cl.
Spec. Mstr. July 16, 2004), mot. for rev. denied, 64 Fed. Cl. 19 (2005), aff’d, 451 F.3d
1352 (Fed. Cir. 2006)). Such a theory need only be “legally probable, not medically or
scientifically certain.” Knudsen v. Sec’y of Health & Human Servs., 35 F.3d 543, 548-49
(Fed. Cir. 1994). Petitioner may satisfy the first Althen prong without resort to medical
literature, epidemiological studies, demonstration of a specific mechanism, or a
generally accepted medical theory. See Andreu v. Sec’y of Health & Human Servs.,
569 F.3d 1367, 1378-79 (Fed. Cir. 2009) (citing Capizzano v. Sec’y of Health & Human
Servs., 440 F.3d 1317, 1325-26 (Fed. Cir. 2006)). However, “[a] petitioner must provide
a ‘reputable medical or scientific explanation’ for [the proposed causal] theory. While it
does not require medical or scientific certainty, it must still be ‘sound and reliable.’”
Boatmon v. Sec’y of Health & Human Servs., 941 F.3d 1351, 1359 (Fed. Cir. 2019)
(citation omitted) (first quoting Moberly v. Sec’y of Health & Human Servs., 592 F.3d
1315, 1322 (Fed. Cir. 2010); then quoting Knudsen, 35 F.3d at 548-49).

In this case, petitioner contends that she suffered an autoimmune axonal
polyneuropathy caused by her vaccination. (ECF No. 95, pp. 3-4.) In furtherance of
that contention, her expert, Dr. Martinez-Arizala, advanced a general causation opinion
based on the concept of molecular mimicry. (Ex. 16, p. 5; Tr. 57-58.) Petitioner argues
that, because molecular mimicry is generally accepted as a mechanism of
autoimmunity, most notably in the context of Guillain-Barré Syndrome, and because
polyneuropathy can likewise be autoimmune, she has therefore satisfied her
preponderant burden of proof. (ECF No. 95, pp. 4-5.) She argues that respondent’s
experts rely on an “unattainably high standard of proof rather than acknowledging the
broader context of the evidence.” (Id. at 3.) In particular, petitioner argues that she is
not obligated to prove either an exact homology or a relevant host antigen to support
her invocation of molecular mimicry, and that her only obligation is to present a
“plausible, biologically tenable theory.” (ECF No. 98, p. 3.) Petitioner’s arguments
relative to Althen prong one are not persuasive.

Of course, petitioner is not obligated to come forward with a specific biologic
mechanism to meet her burden of proof. Kottenstette v. Sec’y of Health & Human
Servs., 861 F. App’x 433, 440-41 (Fed. Cir. June 15, 2021) (citing Knudsen, 35 F.3d at
549 and Simanski v. Sec’y of Health & Human Servs., 671 F.3d 1368, 1384 (Fed. Cir.
2012)). However, because she does seek to meet her burden of proof under Althen
prong one at least in part via presentation of such a mechanism – in this case,
molecular mimicry – the soundness of that assertion must be assessed. E.g., Howard
v. Sec’y of Health & Human Servs., No. 16-1592V, 2022 WL 4869354, at *24 (Fed Cl.
Spec. Mstr. Aug. 31, 2022) (“[P]etitioners are never required to establish [a]

23
mechanism—but they often attempt to do so, and therefore it is reasonable to evaluate
their success in the effort.”), mot. for rev. denied sub nom. Howard v. United States, No.
16-1592V, 2023 WL 4117370 (Fed. Cl. May 18, 2023), aff’d per curiam sub nom.
Howard v. Sec’y of Health & Human Servs., No. 2023-1816, 2024 WL 2873301 (Fed.
Cir. June 7, 2024). That is, although petitioners are not required to prove their theories
in any one way, they must in all events support their proffered theory with sound and
reliable scientific explanation, Boatmon, 941 F.3d at 1359, and provide evidence that
establishes on balance that the vaccine at issue can more likely than not cause the
injury at issue, Cerrone v. Sec’y of Health & Human Servs., 146 F.4th 1113, 1120-23
(Fed. Cir. 2025).

As Dr. Martinez-Arizala explained, molecular mimicry is a concept whereby
“components of the vaccine possess sequence similarities between it and specific
human proteins that results in the cross activation of autoreactive T or B cells,” and that
“[t]his immune cross reactivity causes a reaction of the immune system against the
pathogenic antigens that may harm the similar human proteins, essentially causing
autoimmune disease.” (Ex. 16, p. 5; see also Tr. 57-58.) Petitioner is correct that this is
“a generally accepted scientific principle,” but “mere invocation of the scientific term
does not carry a petitioner’s burden in a Program case.” Deshler v. Sec’y of Health &
Human Servs., No. 16-1070V, 2020 WL 4593162, at *20 (Fed. Cl. Spec. Mstr. July 1,
2020) (citing Forrest v. Sec’y of Health & Human Servs., No. 14-1046V, 2019 WL
925495, at *3 (Fed. Cl. Spec. Mstr. Jan. 28, 2019)). Afterall, a “special master is
entitled to require some indicia of reliability to support the assertion of the expert
witness.” Moberly, 592 F.3d at 1324.

Petitioner provides no citation or explanation to support her suggestion that she
can reasonably invoke molecular mimicry without any demonstration of either homology
or a host antigen. (ECF No. 98, p. 3.) By contrast, Dr. Morel reasonably suggested
that homology, though not enough on its own, is the fair starting point for assessing
molecular mimicry. (Tr. 181-82.) This is consistent with prior program experience,
which has stressed that even the identification of homology, which may be viewed
merely as a threshold finding, “does not necessarily mean the similarity has significance
to the immune system.” Tullio v. Sec’y of Health & Human Servs., No. 15-51V, 2019
WL 7580149, at *15 (Fed. Cl. Spec. Mstr. Dec. 19, 2019), aff’d, 149 Fed. Cl. 448 (2020);
see also Caredio ex rel. D.C. v. Sec’y of Health & Human Servs., No. 17-0079V, 2021
WL 4100294, at *31 (Fed. Cl. Spec. Mstr. July 30, 2021) (“[D]emonstration of homology
alone is not enough to establish a preponderant causation theory.” (emphasis omitted)
(citing Schultz v. Sec’y of Health & Human Servs., No. 16-539V, 2020 WL 1039161, at
*22 n.24 (Fed. Cl. Spec. Mstr. Jan. 24, 2020))), mot. for rev. denied, No. 17-79V, 2021
WL 6058835 (Fed. Cl. Dec. 3, 2021). Thus, for example, in Brayboy, an omnibus
proceeding addressing autoimmune premature ovarian insufficiency, the special master
found it sufficient that the petitioners had, more robustly, “identified cross-reaction
between components of the vaccine and proteins in the body that are directly
responsible for the health and productivity of the organ at issue,” while also noting that
further requiring additional steps, or insisting on direct, testable evidence would
impermissibly heighten petitioner’s burden of proof. Brayboy v. Sec’y of Health &

24
Human Servs., No. 15-183V, 2021 WL 4453146, at *19 (Fed. Cl. Spec. Mstr. Aug. 30,
2021). Ultimately, when assessing theories based on molecular mimicry in light of
petitioner’s preponderant burden of proof, “[t]he line must be drawn somewhere
between speculation and certainty.” Id.

In this case, petitioner has not provided any evidence that suggests that the Tdap
vaccine can cause axonal polyneuropathy via molecular mimicry. As respondent noted
in his post-hearing brief (ECF No. 97, p. 14), Dr. Martinez-Arizala conceded during the
hearing that he has neither proposed a homology that would support molecular mimicry
nor identified a component of the vaccine that would cross-react within the body. (Tr.
103-04.) Instead, Dr. Martinez-Arizala sought to evidence the necessary connection
circumstantially. However, while petitioners are permitted to rely on circumstantial
evidence, Althen, 418 F.3d at 1280, prior petitioners who have successfully relied upon
molecular mimicry have generally presented more substantial, and more persuasive,
evidence, either direct or circumstantial, than is present in this case. E.g., Brayboy,
2021 WL 4453146, at *19 (petitioner prevailed on molecular mimicry theory by
presenting evidence of cross-reaction); E.M. v. Sec’y of Health & Human Servs., No.
14-753V, 2021 WL 3477837, at *36-39 (Fed. Cl. Spec. Mstr. July 9, 2021) (molecular
mimicry supported by proposed homology and identification of corresponding targets
associated with the condition at issue); Pierson v. Sec’y of Health & Human Servs., No.
17-1136V, 2022 WL 322836, at *27-31 (Fed. Cl. Spec. Mstr. Jan. 19, 2022) (petitioner
prevailed on molecular mimicry theory with evidence circumstantially demonstrating a
proposed homology, a relevant autoantibody, and cross-reactive potential); Riese v.
Sec’y of Health & Human Servs., No. 19-477V, 2025 WL 3463267, at *19-22 (Fed. Cl.
Spec. Mstr. Nov. 3, 2025) (petitioner prevailed on molecular mimicry theory with
demonstration of a proposed homology and evidence of a pathogenic antibody).

Dr. Martinez-Arizala first and foremost cited the established link between two
particular flu vaccine formulations (the Swine flu and H1N1) and GBS as “the best
example we have” of post-vaccinal molecular mimicry. (Tr. 58; Ex. 16, pp. 5-6.)
However, Dr. Martinez-Arizala acknowledged that petitioner’s own condition is not
directly analogous to GBS. (Tr. 58-59; Ex. 29, p. 3.) Thus, petitioner’s own condition is
at a minimum one step removed from this body of evidence. As Dr. Morel reasonably
explained, those peripheral neuropathies that are considered immune-mediated tend to
be well-defined and have identified immune processes. (Tr. 170-71.) Accordingly, this
weakens the strength of this evidence as applied to this case.11 Without more, mere
analogy to GBS is not enough to support invocation of molecular mimicry vis-à-vis other
types of peripheral neuropathy. Accord McGill v. Sec’y of Health & Human Servs., No.
15-1485V, 2023 WL 3813524, at *26-28 (Fed. Cl. Spec. Mstr. May 11, 2023) (finding
GBS to be a “flawed” analogy relative to small fiber neuropathy and accepting
respondent’s expert’s testimony that “molecular mimicry involves a specific interaction
that is not generalizable across differing contexts” and that “molecular mimicry is not the

11 To be clear, respondent’s experts do agree that GBS can be at least somewhat informative of the

potential causes of other peripheral neuropathies. (Tr. 208.) Thus, I do not conclude that the proffered
evidence pertaining to the causes of GBS is entirely irrelevant.

25
cause of all autoimmune disease”); Houston v. Sec’y of Health & Human Servs., No. 18-
420V, 2021 WL 4259012, at *16-17 (Fed. Cl. Spec. Mstr. Aug. 19, 2021) (explaining
that “the filed literature establishes that CIDP should not be viewed as merely a ‘chronic’
form of GBS, even though both are peripheral neuropathies involving nerve
demyelination” and that “while there is evidence supporting molecular mimicry as a
disease mechanism driving GBS, Dr. Callaghan explained that there is no comparable
evidence associating molecular mimicry with CIDP”).

Additionally, while examples of other vaccines resulting in presumed molecular
mimicry12 may reasonably challenge Dr. Morel’s assertion that vaccine proteins should
be viewed more skeptically than complete infectious organisms as vehicles for
molecular mimicry (Tr. 180-81), they do nothing to implicate the specific components of
the Tdap vaccine as potential molecular mimics. Instead, petitioner has presented
literature specifically implicating structures in the flu vaccine with the induction of anti-
ganglioside antibodies (Nachamkin et al., supra, at Ex. 53), and has further presented
literature that in turn associates anti-ganglioside antibodies with the axonal variant of
GBS (Hafer-Macko et al., supra, at Ex. 54). Petitioner has not presented any evidence
purporting to demonstrate that the Tdap vaccine (or an any component of the vaccine)
elicits the anti-ganglioside antibodies underlying petitioner’s theory.

Indeed, none of the three articles Dr. Martinez-Arizala cited involving post-Tdap
GBS implicated anti-ganglioside antibodies. (Kongbunkait et al., supra, at Ex. 22
(reporting four cases of GBS arising after diphtheria-tetanus vaccination, and noting that
anti-gangliosides are “believed” to be an explanation for post-vaccination GBS, but
providing no data to indicate that the case subjects had such antibodies); Ammar,
supra, at Ex. 23 (single case report of post-Tdap GBS without any discussion of anti-
ganglioside antibodies); Quast et al., supra, at Ex. 27 (reporting on 22 cases of various
neuropathies following tetanus vaccination, including two cases diagnosed as GBS, with
no discussion of anti-ganglioside antibodies).)

Potentially the strongest piece of evidence suggesting that tetanus-containing
vaccines can cause GBS via molecular mimicry is the 1994 IOM report introduced into
the record as Court Exhibit I. (1994 IOM report, supra, at Ct. Ex. I, pp. 65, 103-07); see
note 3, supra.) However, this publication equates GBS with acute demyelinating
polyneuritis (“AIDP”) whereas an axonal injury is at issue in this case. (1994 IOM
report, supra, at Ct. Ex. I, p. 103.) Moreover, the 1994 IOM report does not invoke anti-
ganglioside antibodies to explain the phenomenon of post-tetanus vaccine GBS. (Id. at
103-07.) Instead, the 1994 IOM report suggests that no specific antibody has been

12 While molecular mimicry is often persuasively hypothesized as the mechanism by which some

formulations of the flu vaccine cause GBS, this has not been definitively established. Assessments of this
causal relationship generally place significant weight on epidemiologic correlation between GBS and the
1976 Swine flu vaccine juxtaposed with evidence showing the pathogenesis of GBS may involve
molecular mimicry as separately demonstrated in the context of C. jejuni infection. (2012 IOM report,
supra, at Ct. Ex. II, pp. 350-63; Schonberger et al., supra, at Ex. C, Tab 9.)

26
observed to occur in more than “a fraction of cases.”13 (Id. at 63.) To that point, Dr.
Martinez-Arizala acknowledged that the anti-ganglioside antibodies he hypothesizes as
the cause of petitioner’s condition are seen in only about half of GBS cases (56%). (Tr.
60-61.)

Dr. Martinez-Arizala’s opinion is otherwise supported only by a series of case
reports generally seeking to implicate tetanus vaccines in the manifestation of various
neuropathies. (Kongbunkait et al., supra, at Ex. 22; Ammar, supra, at Ex. 23; Baust et
al., supra, at Ex. 24; Blunsetin & Kreithen, supra, at Ex. 25; Reinstein et al., supra, at
Ex. 26; Quast et al., supra, at Ex. 27.) Petitioners in this program often highlight the
usefulness of case reports in cases of rare diseases or unusual occurrences. E.g.,
Patton v. Sec’y of Health & Human Servs., 157 Fed. Cl. 159, 166-68 (2021). However,
case reports “do not purport to establish causation definitively, and this deficiency does
indeed reduce their evidentiary value,” even though they are not entirely devoid of
evidentiary value. Paluck ex rel. Paluck v. Sec’y of Health & Human Servs., 104 Fed.
Cl. 457, 475 (2012) (quoting Campbell v. Sec’y of Health & Human Servs., 97 Fed. Cl.
650, 668 (2011)). Based on my review of the specific case reports filed in this case,
they are insufficient to carry petitioner’s burden of proof. Although the six publications
cited by Dr. Martinez-Arizala account for 27 individual cases, they are not uniform in
either clinical presentation or proposed theory of causation (where a theory is even
presented). Ultimately, none of the publications provide any useful data beyond a
purported temporal association. However, “single case reports of Disease X occurring
after Factor Y . . . do not offer strong evidence that the temporal relationship is a causal
one—the temporal relationship could be pure random chance.” Crutchfield v. Sec’y of
Health & Human Servs., No. 09-0039V, 2014 WL 1665227, at *19 (Fed. Cl. Spec. Mstr.
Apr. 7, 2014), aff’d, 125 Fed. Cl. 251 (2014). In fact, Dr. Martinez-Arizala himself
conceded that case reports at best “suggest” a potential causal link. (Tr. 94.)

Setting aside petitioner’s analogy to GBS, none of the four other publications
petitioner presented regarding case reports of post tetanus-vaccination neuropathies
even invoke molecular mimicry generally, let alone implicate anti-ganglioside antibodies
13 Regarding the separate and broader question of whether the Tdap vaccine can cause GBS at all, the

1994 IOM report must be weighed against the IOM’s later 2012 report, which did not maintain the
conclusion that there is adequate evidence to implicate tetanus vaccines as a cause of GBS (2012 IOM
report, supra, at Ct. Ex. II, pp. 586-87). Compare Harris, 2023 WL 2583393, at *24 (the undersigned
explaining of the 1994 and 2012 IOM reports that “the substance of both reports should be weighed to
assess their persuasive value rather than reflexively accepting the latest report to the exclusion of the
earlier report”), with Kaczeroswki v. Sec’y of Health & Human Servs., No. 21-758V, 2025 WL 2798865, at
*34 (Fed. Cl. Spec. Mstr. Aug. 28, 2025) (another special master explaining the view that the 2012 report
“supplanted” the prior report (emphasis omitted)). To be clear, as illustrated by Harris, supra, there are
prior instances in which petitioners have succeeded in providing preponderant evidence that tetanus-
diphtheria and acellular pertussis vaccines can cause GBS. However, that is not the issue addressed
here. Petitioner is not arguing that her Tdap vaccine caused GBS, she is implicitly arguing that the fact
that the Tdap vaccine can cause GBS represents some evidence supporting her invocation of the
mechanism of molecular mimicry to axonal peripheral neuropathies broadly. However, for the reasons
discussed herein, the evidence filed into this record does not meaningfully support that proposition
regardless of whether one were to otherwise conclude that the Tdap vaccine can more likely than not
cause GBS.

27
in particular. (Baust et al., supra, at Ex. 24; Blumstein & Kreithen, supra, at Ex. 25;
Reinstein et al., supra, at Ex. 26; Quast et al., supra, at Ex. 27.) Instead, these reports,
which include conditions affecting the area of the brachial plexus, cite hypersensitivity14
responses as a potential mechanism. (Baust et al., supra, at Ex. 24; Blumstein &
Kreithen, supra, at Ex. 25.) This is also consistent with how the IOM’s 1994 report,
which concluded that the Tdap vaccine can cause brachial neuritis, addressed the
issue. That report distinguished non-demyelinating neuropathies such as brachial
neuritis from GBS and stressed that the etiology for such neuropathies remains
unknown, though hypersensitivity is possible. (1994 IOM report, supra, at Ct. Ex. I, pp.
107-08.) And, importantly, Dr. Martinez-Arizala did not seek to substantiate
hypersensitivity or any other mechanism that could explain how Tdap vaccination can
cause brachial neuritis. In fact, when I asked Dr. Martinez-Arizala during the hearing to
speak to the significance, if any, of the brachial neuritis case reports he had cited, he
was unable to do so. (Tr. 75-77.) Moreover, in contrast to the present case and
consistent with Dr. Morel’s testimony, the 1994 IOM report stressed that, while the
underlying pathogenesis is not well understood, the conclusion that the Tdap vaccine
can cause brachial neuritis is at least partly supported by the fact that it is “a well-
defined clinical syndrome,” which helps support a reliance on case reporting. (1994
IOM report, supra, at Ct. Ex. I, p. 108; Tr. 170-71.)

Finally, I do agree with petitioner that there may be some instances in which
respondent’s experts sought in effect to elevate petitioner’s burden of proof. In
particular, Dr. Morel overstated the degree to which the Tuttle study can be said to
exonerate the Tdap vaccine as a cause of GBS.15 However, this is of no moment.
Petitioner’s case does not fail under Althen prong one because respondent’s experts
disagree. She has failed to meet her Althen prong one burden of proof because she
has herself failed to come forward with evidence to support her proffered theory by a
preponderance of the evidence. Accord Cerrone, 146 F.4th at 1120-23. In sum, Dr.
Martinez-Arizala’s initial report treated the question of general causation very lightly,
essentially identifying the concept of molecular mimicry broadly and citing the above-

14 Though both are immune-mediated mechanisms, molecular mimicry and hypersensitivity are distinct.

Compare 2012 IOM report, supra, at Ct. Ex. II, pp. 93-95 (explaining hypersensitivity), with id. at 99-102
(explaining molecular mimicry).
15 The Federal Circuit has previously stressed that a petitioner is not obligated to prove a case with

epidemiology. Capizzano, 440 F.3d at 1325. Yet, “[n]othing in Althen or Capizzano requires the Special
Master to ignore probative epidemiological evidence that undermines petitioner’s theory.” D’Tiole v. Sec’y
of Health & Human Servs., 726 F. App’x 809, 811 (Fed. Cir. 2018). In this case, Dr. Morel testified that
she based her ultimate opinion as to general causation on large-scale epidemiology and that the Tuttle
study in particular is “quite convincing.” (Tr. 226-28, 233.) She even went as far as to agree that the
Tuttle study may be the “only” reason she disagrees that the Tdap vaccine can cause GBS. (Id. at 228-
29.) However, in its 2012 report, the IOM declined to weigh the Tuttle study in its assessment of the
available epidemiologic evidence regarding post-Tdap GBS because it used data from passive
surveillance and lacked an unvaccinated comparison population, ultimately concluding that there is
insufficient epidemiologic data to either accept or reject a causal relationship. (2012 IOM report, supra, at
Ct. Ex. II, p. 586.) Accordingly, I do not find Dr. Morel’s reliance on the Tuttle study to be persuasive,
leaving her causal opinion as to post-Tdap GBS largely reliant on a lack of large scale epidemiology,
which petitioner is not required to produce.

28
discussed case reports with little to nothing that would unite the case reports and the
theory.16 (Ex. 16, pp. 5-7.) And, despite the question of general causation having been
contested by respondent’s experts, he did not revisit the question of whether the Tdap
vaccine can cause peripheral neuropathies in either of his supplemental reports. (Exs.
29, 42.) It was not until presenting Dr. Martinez-Arizala’s rebuttal testimony that
petitioner sought to bolster petitioner’s theory by discussing several articles pertaining to
the validity of molecular mimicry as a concept and the degree of homology that can
support its invocation. (Tr. 239-42; Fujinami & Oldstone, supra, at Ex. 74; Gautam et
al., supra, at Ex. 75; Steinman, supra, at Ex. 76.) However, the issue here is not the
general viability of molecular mimicry, it is whether it is reasonably applied to this
combination of vaccination and injury. Moreover, parsing the degree of homology that
could support molecular mimicry is essentially irrelevant where there has been no
presentation of a proposed homology in the first place.

In light of all of the above, and considering the record as a whole, petitioner has
not preponderantly demonstrated that the Tdap vaccine can cause autoimmune axonal
polyneuropathy.

b. Althen prongs two and three

Because I have concluded that petitioner has not preponderantly demonstrated
that the Tdap vaccine can cause autoimmune axonal peripheral neuropathy, it is not
necessary to address in detail whether the vaccine did so in this particular case. Given
the outcome regarding Althen prong one, by definition it likely did not. Thus, I address
Althen prongs two and three only briefly. Trollinger v. Sec’y of Health & Human Servs.,
167 Fed. Cl. 127, 142 (2023) (affirming the Chief Special Master’s dismissal based on a
dispositive finding that petitioner had not satisfied Althen prong one). In particular, I
note out of an abundance of caution that the evidence relevant to Althen prong two is
not so robust as to otherwise influence the analysis under Althen prong one. See
Patton, 157 Fed. Cl. at 169 (finding treating physician opinions relevant to assessing the
reliability of the expert’s theory of general causation).

The third Althen prong asks whether the timing of injury in this specific case
aligns with what would be expected under the general theory presented under Althen

16 In the post-hearing briefing, petitioner’s counsel suggested that “[t]his case would have been settled

when I started practicing in this program.” (ECF No. 95, p. 3.) It is important to note, however, that even
accepting counsel’s representation at face value, the history of reasoned decisions in the program should
not have given petitioner any comfort that her proffered theory would be viewed as a settled matter.
Cases alleging that the Tdap vaccines have caused neuropathies have resulted in mixed outcomes.
Compare, e.g., Swaiss v. Sec’y of Health & Human Servs., No. 15-286V, 2019 WL 6520791 (Fed. Cl.
Spec. Mstr. Nov. 4, 2019) (finding a petitioner entitled to compensation for small fiber neuropathy caused
by a Tdap vaccine in part based on the assumption it constitutes a variant of GBS), with K.A. v. Sec’y of
Health & Human Servs., No. 16-989V, 2022 WL 20213037 (Fed. Cl. Spec. Mstr. Apr. 18, 2022) (denying
entitlement, distinguishing Swaiss, and explaining why a history of settlement of cases alleging Tdap-
caused GBS do not suggest the causal relationship is settled); see also Lapierre v. Sec’y of Health &
Human Servs., No. 17-227V, 2019 WL 6490730 (Fed. Cl. Spec. Mstr. Oct. 18, 2019) (finding a lack of
preponderant evidence that the Tdap vaccine can cause an unspecified form of sensory neuropathy).

29
prong one. The second Althen prong requires preponderant proof of a logical sequence
of cause and effect, which is usually supported by facts derived from petitioner’s
medical records.17 Althen, 418 F.3d 1278; Andreu, 569 F.3d at 1375-77; Capizzano,
440 F.3d at 1326; Grant, 956 F.2d at 1148. While the opinions of treating physicians
are often favored, Capizzano, 440 F.3d at 1326, a petitioner may support a cause-in-
fact claim through presentation of either medical records or an expert medical opinion.
See § 300aa-13(a).

Here, there is no apparent dispute that petitioner’s neuropathy arose about two-
weeks post-vaccination as petitioner argues. (Tr. 116.) Moreover, had petitioner
preponderantly established her theory of causation, the notion that molecular mimicry
could manifest a peripheral neuropathy within that timeframe would not necessarily be
controversial. Afterall, the Table Injury of post-flu vaccine GBS carries a causal
presumption if onset occurs between 3-42 days post-vaccination. 42 C.F.R. § 100.3(a).
Respondent contests that petitioner has met her burden of proof under Althen prong
three, but only to the extent she has not met her burden under Althen prong one. He
does not argue that the timing is otherwise confounding. (ECF No. 97, pp. 22-23.)

Nonetheless, temporal association alone is not enough to satisfy petitioner’s
burden of proof. See, e.g., Veryzer v. Sec’ y of Health & Hu man Servs., 100 Fed. Cl.
344, 356 (2011) (explaining that “a temporal relationship alone will not demonstrate the
requisite causal link and that petitioner must posit a medical theory causally connecting
[the] vaccine and injury”), aff’d per curiam sub nom. Veryzer v. United States, 475 F.
App’x 765 (Fed. Cir. 2012); A.Y. v. Sec’y of Health & Human Servs., 152 Fed. Cl. 588,
595 (2021); Forrest v. Sec’y of Health & Human Servs., No. 10-032V, 2017 WL
4053241, at *18 (Fed. Cl. Spec. Mstr. Aug. 10, 2017); Cozart v. Sec’y of Health & Human
Servs., No. 00-590V, 2015 WL 6746616, at *18 (Fed. Cl. Spec. Mstr. Oct. 15, 2015),
mot. for rev. denied, 126 Fed. Cl. 488 (2016); Crosby v. Sec’y of Health & Human Servs.,
No. 08-799V, 2012 WL 13036266, at *37 (Fed. Cl. Spec. Mstr. June 20, 2012). Afterall,
Althen prong two is not without meaning.18 Capizzano, 440 F.3d at 1326-27.

17 Medical records are generally viewed as trustworthy evidence. Cucuras v. Sec’y of Health & Human
Servs., 993 F.2d 1525, 1528 (Fed. Cir. 1993). These records are generally contemporaneous to the
medical events and “contain information supplied to or by health professionals to facilitate diagnosis and
treatment of medical conditions. With proper treatment hanging in the balance, accuracy has an extra
premium.” Id. However, medical records and/or statements of a treating physician’s views do not per se
bind the special master. § 300aa-13(b)(1) (providing that “[a]ny such diagnosis, conclusion, judgment,
test result, report, or summary shall not be binding on the special master or court”); Snyder v. Sec’y of
Health & Human Servs., 88 Fed. Cl. 706, 745 n.67 (2009) (reasoning that “nothing . . . mandates that the
testimony of a treating physician is sacrosanct—that it must be accepted in its entirety and cannot be
rebutted”).
18 The Capizzano Court described the circumstances in which Althen prong two may be a stumbling block

as follows:

There may well be a circumstance where it is found that a vaccine can cause the injury at
issue and where the injury was temporally proximate to the vaccination, but it is illogical to
conclude that the injury was actually caused by the vaccine. A claimant could satisfy the
first and third prongs without satisfying the second prong when medical records and
medical opinions do not suggest that the vaccine caused the injury, or where the probability

30
Regarding Althen prong two, the critical issue is that the evidence does not
preponderate in favor of a finding that petitioner’s own polyneuropathy is autoimmune.
Although each parties’ neurology expert was willing to identify a potential autoimmune
trigger (the vaccine for Dr. Martinez-Arizala and a urinary tract infection for Dr.
Donofrio19), Dr. Donofrio ultimately explained that it is “always the case” that
polyneuropathy is not in and of itself suspicious for autoimmunity. (Tr. 157-58.) Both
parties’ neurology experts agreed that autoimmunity is only one of numerous potential
causes of polyneuropathy. (Id. at 52-53, 115-16.) And Dr. Donofrio further explained
that, even as some of the most common causes of neuropathy are not at issue, such as
alcohol abuse, vitamin deficiency, or diabetes, there are over 100 known causes of
peripheral neuropathy and it is not unusual for the etiology of a patient’s polyneuropathy
to remain unknown even after a thorough work up. (Id. at 115-16, 141-42, 157-58.)

In this particular case, respondent’s experts have additionally noted several
aspects of petitioner’s clinical presentation that do not readily support the conclusion
that her polyneuropathy was autoimmune. Specifically: testing for inflammatory
markers (CRP and ESR) did not show evidence of an inflammatory process (Ex. C, p. 3;
Ex. F, p. 1); an extensive panel testing for autoimmune conditions and antibodies20 was
completely negative (Tr. 118-21); spinal MRI was negative for nerve root
enhancement21 (Id. at 121-26); and the neuropathy was axonal, rather than
demyelinating (Id. at 129). On petitioner’s behalf, Dr. Martinez-Arizala, opined that none
of these considerations rule out an autoimmune neuropathy (Id. at 59-63, 70, 86-87,
246-48) and respondent’s expert, Dr. Donofrio, likewise conceded as much (Id. at 140-
46). However, Dr. Martinez-Arizala did acknowledge that all of the tests performed in
petitioner’s case were negative for the cause of her neuropathy. (Id. at 64.)

of coincidence or another cause prevents the claimant from proving that the vaccine
caused the injury by preponderant evidence.

440 F.3d at 1327.

19 Notably, neither of these proposed autoimmune triggers is persuasive for opposite reasons. Although
the fact of petitioner’s vaccination is not disputed, its role as an initiator of an autoimmune neuropathy is
not preponderantly supported for the reasons discussed under Althen prong one. Conversely, Dr.
Martinez-Arizala agreed on petitioner’s behalf that a urinary tract infection can cause neuropathy;
however, he was nonetheless persuasive in explaining why it is unlikely that petitioner suffered a urinary
tract infection during the relevant period. (Tr. 90-91, 244-45.)

20 During the hearing, petitioner’s counsel made a point of stressing on cross-examination that petitioner’s

testing included only one of multiple anti-ganglioside antibodies that have been associated with GBS. (Tr.
144-45, 208-15.) Dr. Morel suggested, however, that the one antibody that was tested was the most
likely antibody to be implicated. (Id. at 210-15.) While petitioner is correct that the antibody testing that
was performed is not definitive with respect to the absence of any and all anti-ganglioside antibodies, the
assertion that petitioner had any of those other anti-ganglioside antibodies remains speculative.

21 The significance of this finding is not necessarily clear with respect to petitioner’s first MRI because it

was performed without a contrast medium. (Tr. 147-48.) However, Dr. Donofrio also opined that
petitioner’s second MRI, which did use a contrast medium, was also performed at a time when it would
have been expected to detect nerve root enhancement. (Id. at 125-26, 154.)

31
Without treating any one of the above-cited factors as dispositive, they do reveal
a significant absence of any affirmative evidence of autoimmunity despite relevant
diagnostics having been performed. Accord Baldwin v. Sec’y of Health & Human
Servs., 151 Fed. Cl. 431, 447 (2020) (explaining with regard to Althen prong two that
“[p]etitioner was required to prove by a preponderance of the evidence that one of her
expert’s theories actually occurred . . . [but] [p]etitioner did not identify anything in her
medical records to support any of her experts’ various theories by a preponderance of
the evidence”). Although Dr. Martinez-Arizala contended that an autoimmune
neuropathy can be diagnosed based on clinical presentation in the absence of positive
lab results (Tr. 70), he also explained that all neuropathies basically have the same
manifestations (Id. at 64). The only affirmative clinical evidence Dr. Martinez-Arizala
cited to support an autoimmune process was petitioner’s rash, which both he and
petitioner’s treating physician (Dr. Carlson) assumed to be a vasculitis (Id. at 63, 71-72;
Ex. 1, p. 83); however, Dr. Donofrio explained that “it’s really unclear why she had a
rash. And rashes can be very difficult to associate with a patient’s illness.” (Tr. 133.)
Thus, Dr. Martinez-Arizala ultimately conceded of the rash that it “could have been
anything.” (Id. at 252.)

Indeed, petitioner’s polyneuropathy was noted to have an unclear etiology
throughout much of her treatment history. As among her treating physicians, petitioner
cites only Dr. Carlson as opining that her condition was vaccine-caused. (ECF No. 95,
p. 6.) Dr. Carlson opined of petitioner’s polyneuropathy that the

most likely etiology is an acute autoimmune neuropathy associated with
tetanus vaccination. Rare post-vaccinal neuropathies can develop often
related to a leukocytoclastic vasculitis. It is intriguing that this patient had a
truncal rash associated with peripheral nerve symptomatology early in her
presentation which is likely a dermatologic comorbid condition.

(Ex. 1, p. 83.) However, this opinion is not strong evidence. First, it appears to be
premised on the notion that petitioner suffered a leukocytoclastic vasculitis, but such an
etiology for petitioner’s rash is not preponderantly established. (Dr. Carlson was aware
of the rash by history only. (Id. at 81.)) Second, it appears to have been only a
tentative assessment insofar as the assessment goes on to state that “[w]e will proceed
with further testing to assess for inflammation, autoimmune disease or infection not
already assessed.” (Id. at 83.)

Ultimately then, petitioner is left only to stress the fact that her neuropathy first
arose post-vaccination and that many alternative causes were ruled out. (ECF No. 95,
p. 6; ECF No. 98, pp. 3-4; Tr. 59, 63.) However, the Federal Circuit has explained that,
“[a]lthough probative, neither a mere showing of a proximate temporal relationship
between vaccination and injury, nor a simplistic elimination of other potential causes of
the injury suffices, without more, to meet the burden of showing actual causation.”
Althen, 418 F.3d at 1278 (citing Grant, 956 F.2d at 1149); Hibbard v. Sec’y of Health &
Human Servs., 698 F.3d 1355, 1364-65 (Fed. Cir. 2012) (holding the special master did

32
not err in resolving the case pursuant to Althen prong two when respondent conceded
that petitioner met Althen prong three).

For all these reasons, petitioner has not met her burden of proof with respect to
specific causation under Althen prong two.

VI. Conclusion

Although petitioner has my sympathy for the pain and discomfort she has
endured, for all the reasons discussed above, I find that she has not met her burden of
proof. Therefore, pursuant to § 300aa-12(d)(3)(A) and Vaccine Rule 10, this decision
concludes that petitioner is not entitled to an award of compensation. Absent a timely
motion for review, the Clerk is directed to enter judgment dismissing this case for
insufficient proof in accordance with Vaccine Rule 11(a).

IT IS SO ORDERED.

s/Daniel T. Horner
Daniel T. Horner
Special Master

33

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/cases/11335904. Public record. Not legal advice.